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CHAPTER I 
 
BACKGROUND 
 
Introduction 
Several unrelated viruses, including adenovirus, herpes simplex virus, poliovirus, 
reovirus, and rhinovirus, utilize receptors that are members of the immunoglobulin 
superfamily (IgSF) (4, 10, 49, 51, 82).  IgSF members are heterogeneous in tissue 
distribution and biological function, but all share a common structural motif: the Ig fold.  
The Ig fold is a sandwich of two β sheets whose component β-strands are connected with 
a distinct topology (55).  Members of the IgSF are commonly associated with functions 
in the immune system and include antibodies, antigen receptors, CD4, CD8, and class I 
and II major histocompatibility complex (MHC) proteins.  Several IgSF virus receptors, 
including the reovirus receptor junctional adhesion molecule-A (JAM-A), are located in 
either tight junctions (TJs) or adherens junctions of polarized epithelial and endothelial 
cells (28, 80, 126, 127).  Why viruses would utilize IgSF receptors located in cell-cell 
junctions is largely an unanswered question.  In my dissertation research, I have 
attempted to define the role of JAM-A in reovirus pathogenesis.  A detailed 
understanding of how reovirus interactions with JAM-A mediate host infection may 
illuminate principles of pathogenesis common to the viruses that bind junctional IgSF 
receptors. 
Mammalian orthoreoviruses (reoviruses) form nonenveloped, double-shelled 
particles containing a genome of 10 segments of double-stranded (ds) RNA (Figure I-1) 
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(114).  The prototype strains of reovirus were isolated in the 1950s (103, 111).  Since that 
time, studies with reovirus have yielded several important discoveries in virology.  For 
example, one of the first virology studies that employed genetic techniques identified 
allelic traits that segregated with particular reovirus gene segments (117).  Building on 
these studies, it was first demonstrated with reovirus that a viral receptor attachment 
protein can mediate viral tropism and virulence (149).  For nearly half a century, reovirus 
has proven to be a highly tractable experimental model for studies of viral pathogenesis 
(143). 
When this work was initiated, JAM-A had been identified as a reovirus receptor, 
but it was unknown how JAM-A mediates reovirus infection in vivo.  In Chapter II, I 
report that JAM-A is required for systemic infection of mice by reovirus.  In Chapter III, 
I present work demonstrating that JAM-A is dispensable for reovirus neurotropism but 
required for promoting dissemination of reovirus within the infected host.  In Chapter IV, 
I report that JAM-A mediates establishment of reovirus viremia and efficient infection of 
endothelial cells.  These findings demonstrate that JAM-A is required for systemic 
dissemination of reovirus and suggest a role for junction-associated viral receptors in 
viremic dissemination. 
 
Reovirus tropism and pathogenesis 
Reoviruses have a wide geographic distribution, and virtually all mammals, 
including humans, serve as hosts for infection (134).  However, reovirus is rarely 
associated with disease, except in the very young (76, 128).  Reovirus strains can be  
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FIGURE I-1. A reovirus virion. (A) Schematic representation of a reovirus virion depicting 
10 gene segments, a double-layered viral capsid, and the receptor attachment protein σ1 
inserted into pentamers of the structural protein λ2. (B) Cryoelectron microscopic image 
reconstruction of a reovirus virion. Major outer capsid proteins are pseudocolored and 
labeled. σ1 molecules are drawn schematically. Image adapted from Nason et al (89). 
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classified into three distinct serotypes based on neutralization and hemagglutination-
inhibition tests (107, 111, 122).  The prototype strain for reovirus type 1, type 1 Lang 
(T1L), was isolated from a healthy child.  The prototype strains for reovirus types 2 and 
3, type 2 Jones (T2J) and type 3 Dearing (T3D), respectively, were isolated from children 
with diarrhea (103, 111).  Approximately 50% of healthy children acquire antibodies to 
T3D by the age of 5 years (125).   
The natural portal of entry for reoviruses into the host is from the respiratory and 
enteric tracts (111).  Newborn mice are exquisitely sensitive to reovirus infection and are 
the preferred experimental system for studies of reovirus pathogenesis (143).  Infection of 
newborn mice by T1 and T3 reovirus strains via the enteric tract has been extensively 
studied (94).  Following peroral inoculation, the reovirus outer capsid is processed by 
host intestinal proteases, resulting in the transition from the intact virion to a disassembly 
intermediate known as the infectious subvirion particle (ISVP) (13).  Reovirus ISVPs 
specifically adhere to intestinal microfold (M) cells (Figure I-2), which overlie 
submucosal collections of lymphoid tissue called Peyer’s patches (1, 6, 155).  M cells are 
unique epithelial cells specialized for transepithelial transport of microbes and antigen 
(68).  Virus is transported across M cells within endocytic vesicles and delivered to the 
basolateral surface (153-155).  Reovirus antigen is then observed in mononuclear cells 
and dendritic cells of intestinal Peyer’s patches (45, 61, 85, 155).  By 48 hours 
postinoculation, reovirus antigen is observed in epithelial cells of the ileum (109).  
Reovirus T1L and T3D differ in the capacity to infect the intestine following peroral 
inoculation, a property that segregates with the viral S1 and L2 genes (12).  This  
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FIGURE I-2. Reovirus T1L binds and infects M cells that overlie Peyer’s patches. (A) An 
electron micrograph demonstrating T1L virions (arrow) adhering to the luminal (L) surface of 
an M cell (M) in a closed ileal loop 30 minutes after virus inoculation. The M cell surrounds a 
mononuclear cell (N) and borders two absorptive (A) cells that lack adherent virus (x13,400). 
Inset: higher magnification of M cell surface with adherent virions (x38,800). (B) A 
photomicrograph of adult mouse intestine 48 h after inoculation with 5 x 109 PFU T1L 
demonstrates reovirus antigen-positive (arrowhead) M cells (m) overlying Peyer’s patches 
(PP). Images adapted from Wolf et al (155) (A) and Rubin et al (109) (B). 
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difference in intestinal infection is due to proteolytic cleavage of the T3D σ1 attachment 
protein, which is encoded by the S1 gene (23).  I helped to demonstrate that a T3D virus 
containing a mutation that abolishes this cleavage site in σ1 replicates in the intestine to 
higher titer than T3D (Appendix B, 66).   
Both T1 and T3 strains disseminate systemically and invade the central nervous 
system (CNS) following peroral inoculation of newborn mice, but they do so via different 
modes of spread and produce distinct pathologic consequences.  Reovirus T1 spreads 
from the intestine to the mesenteric lymph node and spleen within 24 hours of 
inoculation, presumably via hematogenous routes (61).  In contrast, reovirus T3 clone 9 
spreads from the intestine to the myenteric plexus to the dorsal motor nucleus of the 
vagus nerve and thus uses a neural route to spread from the intestine to the CNS (85).  
Once in the CNS, T1 reovirus infects ependymal cells (136, 149), resulting in 
hydrocephalus (148).  T3 reovirus exhibits strikingly different tropism within the CNS, 
infecting neurons in the cortex, thalamus, and hippocampus (Figure I-3) (85, 136, 149) 
and causing lethal encephalitis (128, 148).   
The serotype-determining S1 gene of reovirus mediates differences between T1 
and T3 strains in mode of spread, CNS tropism, and neurovirulence (135, 136, 148, 149).  
S1 gene product σ1 is a filamentous, trimeric molecule that extends from the virion 
surface (48) and mediates viral attachment to host-cell receptors (4, 71, 147).  In addition 
to σ1, the S1 gene also encodes a small nonstructural protein, σ1s in an overlapping 
reading frame.  The σ1s protein is not required for growth in cell culture but is thought to 
mediate reovirus-induced G(2)/M cell-cycle arrest (42, 59, 99, 106, 113, and K. W. 
Boehme and T. S. Dermody, manuscript in preparation).   
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FIGURE I-3. T3 reovirus tropism in the brain. (A) A coronal brain section from an 
uninoculated 9-day-old mouse pup exhibits normal cellular architecture with hematoxylin and 
eosin (H&E) stain. CG, cingulate gyrus; FPX, frontoparietal cortex; S, subiculum; DG, 
dentate gyrus; THA, thalamic nuclei; CA1-4, hippocampal regions. (B) A coronal brain 
section from a 9-day-old mouse pup 7 days following intracranial inoculation with T3D 
demonstrates abnormal cytoarchitecture, massive cell loss, and minor inflammation 
throughout the cortical, hippocampal, and thalamic regions. Arrows point to areas of severe 
viral injury. (C) A coronal brain section from a 9-day-old mouse pup 7 days following 
intracranial inoculation with T3D stained for reovirus antigen (red) shows strong positive 
staining throughout the cortical, hippocampal, and thalamic regions of the brain. Neurons are 
counterstained with fluorescent Nissl stain (green cells). Images adapted from Richardson-
Burns et al (105). 
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Attachment and internalization of reovirus 
 The first step in a viral infectious cycle is the engagement of receptors on the 
surface of host cells.  Findings from several different virus families indicate that viral 
attachment to cells often involves multiple interactions between several viral and cellular 
molecules (33).  The reovirus attachment protein σ1 forms an elongated fiber with a 
compact globular head at the C-terminus (26, 47) and binds JAM-A (4) and carbohydrate.  
The σ1 head mediates JAM-A binding, whereas residues in the σ1 tail, close to the 
midpoint of the molecule, mediate T3 σ1 binding to sialic acid (23, 24).  A region in the 
tail just beneath the head mediates T1 σ1 binding to a carbohydrate that has not been 
definitively identified (24, 57).  
The contribution of sialic acid to cellular attachment and host virulence has been 
studied using monoreassortant reoviruses containing the σ1-encoding S1 gene of either 
nonsialic acid-binding strain T3C44 (T3SA-) or sialic acid-binding strain T3C44-MA 
(T3SA+) (3, 5).  The remaining nine genes of T3SA+ and T3SA- derive from T1L.  
These virus strains are capable of growth in the intestine because their σ1 does not share 
cleavage susceptibility with the T3D σ1 (23).  T3SA+ and T3SA- differ in sialic acid-
binding capability by virtue of a single substitution (Leu204 to Pro) in the σ1 tail (25).  
Studies using these virus strains indicate that multiple, low-affinity reovirus-sialic acid 
interactions enhance initial adhesion of the virus to the cell surface and facilitate later, 
higher affinity binding to JAM-A (3).  Pathogenesis studies using these strains suggest 
that the capacity to bind sialic acid enhances the kinetics of dissemination, increases 
yields in target organs, confers tropism to bile duct epithelial cells, and mediates an 
obstructive liver disease in mice similar to human infantile biliary atresia (5).   
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The entry and disassembly of reovirus in a cell is a complex, yet coordinated, 
program and requires several viral outer-capsid components and host cell molecules.  
After engaging receptors, reovirus is internalized into cells via a mechanism dependent on 
β1 integrin (72).  The β1 integrin NPXY motifs, which are potential sites of tyrosine 
phosphorylation and serve as endocytic sorting signals (14), are required for functional 
reovirus entry (73).  Studies suggest that reovirus is internalized via clathrin-dependent 
endocytosis (15, 16, 41, 110, 124).  Reovirus subsequently undergoes stepwise 
disassembly within minutes of internalization that is dependent on acidic pH (77, 124) 
and endosomal cysteine-containing proteases cathepsins B and L (39).  This disassembly 
generates well-defined intermediates.  The ISVP lacks the outer-capsid protein σ3 and 
contains two new particle-associated peptides, δ and φ, generated by cleavage of the 
outer-capsid protein µ1 (16, 22, 119, 124).  ISVPs are further processed to ISVP*s by 
loss of σ1 and conformational rearrangement of δ and φ.  The ISVP* penetrates 
endosomes to deliver transcriptionally active viral cores into the cytoplasm (20, 21, 92, 
93).   
 
JAM-A is a reovirus receptor 
Evidence accumulated in the past twenty years had indicated that the σ1 head 
promotes receptor interactions that are distinct from interactions with sialic acid mediated 
by the σ1 tail (7, 24, 25, 37, 38, 62, 91, 120, 121, 131).  Our laboratory employed a flow 
cytometry-based expression-cloning approach to identify a receptor bound by the 
reovirus σ1 head (4).  T3SA- was used as the affinity ligand to avoid isolating 
glycosylated molecules that might not interact specifically with σ1.  A cDNA library 
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generated from NT2 cells, a human testicular embryonal carcinoma cell line with 
epithelial-like properties in culture, was selectively enriched for cDNAs that confer 
binding of fluoresceinated virions to transfected cells.  Four clones conferred virus 
binding; each encoded human JAM-A (hJAM-A).  hJAM-A-specific monoclonal 
antibodies were found to inhibit T1 and T3 reovirus binding and infection.  Expression of 
hJAM-A and murine JAM-A (mJAM-A) in nonpermissive cells permitted T1 and T3 
reovirus growth.  The σ1 protein was demonstrated to bind directly to hJAM-A with an 
apparent KD of approximately 6×10-8 M (4).  Together, these findings indicate that both 
hJAM-A and mJAM-A serve as receptors for T1 and T3 reovirus.  Later work 
demonstrated that hJAM-A, but not the related proteins hJAM-B, hJAM-C, or human 
coxsackievirus and adenovirus receptor (hCAR), serves as a receptor for both prototype 
and field-isolate strains of all three reovirus serotypes (18, 101).  Currently, JAM-A is the 
only known proteinaceous receptor for reovirus. 
 
Interactions of JAM-A and σ1 
Since the identification of JAM-A as a reovirus receptor, many structural and 
functional details of its interaction with σ1 have been elucidated.  A surface at the base of 
the σ1 head domain predicted to bind JAM-A was identified by mapping σ1 residues 
conserved among the three serotypes onto the crystal structure of σ1 (18, 26).  The crystal 
structure of the extracellular region of hJAM-A revealed two Ig-type domains with a 
pronounced bend at the domain interface (Figure I-4 A).  Two hJAM-A molecules form a 
dimer via their membrane distal V-type Ig domains (D1 domains) similar to that observed 
in the mJAM-A crystal structure (Figure I-4 B) (67, 101).  Chimeric and domain deletion  
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FIGURE I-4. Crystal structures of the hJAM-A and mJAM-A extracellular domains. (A-B) 
Ribbon drawings of the hJAM-A dimer (A) and the mJAM-A dimer (B), with one monomer 
shown in orange and the other in blue. Disulfide bonds are shown in green. Dimerization is 
mediated by the membrane-distal D1 immunoglobulin domain. Both human and murine 
JAM-A serve as reovirus receptors. Images adapted from Prota et al (101) (A) and Kostrewa 
et al (67) (B) by Eva Kirchner. 
 
 
 
mutants of hJAM-A were used to demonstrate that the D1 domain of hJAM-A is required 
for reovirus attachment and infection (46).  A structure-guided mutational analysis of the 
JAM-A dimer interface revealed that T3D σ1 binds to monomers of JAM-A via residues 
found mainly on beta-strands C and C' of the JAM-A dimer interface (52).  Similar 
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analyses using T1L and T2J demonstrated that the residues of JAM-A that are required 
for binding to these strains are similar but not identical to those required for T3D binding 
(52).  A crystal structure has been solved of the amino-terminal domain of JAM-A in 
complex with the T3D σ1 head (E. Kirchner, K. M. Guglielmi, T. S. Dermody, and T. 
Stehle, manuscript in preparation).  This structure elucidates contact sites in each 
molecule and reveals that each σ1 head domain binds to one JAM-A monomer (Figure I-
5) (E. Kirchner, K. M. Guglielmi, T. S. Dermody, and T. Stehle, manuscript in 
preparation).   
Interactions between T3D σ1 and JAM-A parallels other virus-receptor systems.  
One such close parallel is the adenovirus fiber-CAR interaction.  Adenovirus and 
reovirus belong to different virus families and share few common properties, but both are 
nonenveloped and use an attachment receptor with head-and-tail morphology (50).  The 
key structural features shared by σ1 and fiber include defined regions of flexibility within 
the tail, in part composed of an unusual triple β-spiral motif, and head domains that are 
formed by an 8-stranded β-barrel with identical β-strand connectivity (26, 139, 140, 157).  
Each viral attachment protein engages its receptor, a cell-surface, two-Ig domain, dimeric 
host protein expressed at cellular junctions, by interacting with the dimer interface and its 
top loops (11, 140, and E. Kirchner, K. M. Guglielmi, T. S. Dermody, and T. Stehle, 
manuscript in preparation).  Moreover, CAR and JAM-A are related members of the 
JAM/cortical thymocyte marker of Xenopus (CTX) family.  The crystal structures of each 
virus in complex with its receptor indicate that although the viral attachment proteins 
engage their receptors using different binding sites, the viral protein-bound area of the  
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FIGURE I-5. Crystal structure of the T3D σ1 head-JAM-A D1 complex. (A, B) Ribbon 
drawings of the complex between trimeric σ1 head and monomeric JAM-A D1, viewed along 
the three-fold symmetry axis (A) and from the side (B). σ1 head monomers are shown in 
blue, yellow, and red; D1 is shown in green. (C) Surface representation of the contact area of 
reovirus σ1 head (left, orange) and D1 (right, green). Interacting partners are shown as ribbon 
traces. (D) Ribbon drawings of D1 (left) and σ1 head (right). Secondary structure elements 
are labeled. Contact residues (distance cutoff 4 Å) in the σ1 head-D1 interface are colored 
green (D1) or orange (σ1H). 
 
 
 
host receptor is similar (E. Kirchner, K. M. Guglielmi, T. S. Dermody, and T. Stehle, 
manuscript in preparation).   
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Roles of JAM-A in the host 
The JAM family of proteins are IgSF members involved in epithelial barrier 
function, vascular permeability, and leukocyte transmigration (8, 146).  In adult mice, 
JAM-A is expressed on epithelium and endothelium of a wide variety of organs and is 
also found on dendritic cells, lymphocytes, monocytes, macrophages, neutrophils, and 
platelets (8, 19, 80).  JAM-A contains two extracellular Ig-like domains, a short 
transmembrane region, and a cytoplasmic tail possessing a PDZ-domain-binding motif 
(80, 152).  The PDZ-binding motif facilitates the binding of JAM-A to TJ-associated 
cytoplasmic proteins such as zonula occludens-1 (ZO-1) (40), calcium/calmodulin-
dependent serine protein kinase (CASK) (79), and multi-PDZ domain protein 1 (MUPP1) 
(56).  JAM-A forms dimers and tetramers (67, 101).   
JAM-A is an integral component of TJs (80), which form a barrier to intercellular 
passage of water and solutes (115).  In this context, JAM-A plays a key role in leukocyte 
diapedesis in inflammation (146).  Redistribution of JAM-A from cellular junctions to the 
apical surface occurs during an inflammatory response (96, 98) and is thought to allow 
JAM-A to engage circulating leukocytes for diapedesis through endothelium (118, 146).  
The interaction of JAMs with leukocyte integrins is thought to be important for immune 
cell diapedesis.  Specifically, the membrane-proximal Ig domain (D2 domain) of 
endothelial JAM-A engages the leukocyte β2 integrin LFA1 (97).  Also, endothelial 
JAM-A can interact in cis with integrin αvβ3 (87, 88).  JAM-A expression influences the 
expression of β1 integrins (75), and expression of dimerization-defective JAM-A leads to 
internalization of β1 integrin from the cell surface (116).  In addition, dimerization of 
platelet and endothelial JAM-A in trans facilitates platelet adhesion to cytokine-
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stimulated endothelium.  Furthermore, JAM-A may be an evolutionary precursor to 
antigen-recognizing receptors and antigen-presenting molecules.  Du Pasquier and 
colleagues point out that the JAM/CTX and nectin families of proteins are the most likely 
candidates found in urochordate and cephalochordate genomes to have duplicated and 
given rise to elements of the human adaptive immune system (36).  Both of these protein 
families are notable for serving as virus receptors, and it has been proposed that 
interactions between viruses and these receptors may have driven the evolution of the 
adaptive immune system (36).  
Despite the important functions of JAM-A in the host, JAM-A-/- mice are viable 
and display no defects in organ development and morphology (19).  In addition, these 
mice do not have altered numbers of circulating platelets, lymphocytes, neutrophils, or 
monocytes (19).  However, the colonic mucosa of JAM-A-/- mice demonstrates increased 
neutrophil infiltration, large lymphoid aggregates, and increased permeability, which is 
specific to epithelial cells (70).  JAM-A-/- mice also exhibit decreased leukocyte 
transmigration from blood to tissue in several models of inflammation and injury (30, 64, 
156, 158).  In addition, JAM-A-/- mice demonstrate enhanced dendritic cell migration 
from skin to lymph node associated with increased contact hypersensitivity (19).  A role 
for JAM-A in angiogenesis was highlighted by a study in which fibroblast growth factor-
2-induced microvessel sproutings were inhibited in JAM-A-/- mouse tissue (29).   
JAM-A also interacts with microbes.  JAM-A serves as a receptor for all three 
serotypes of reovirus (18) and feline calicivirus (74) and is also targeted by a bacterium.  
Helicobacter pylori translocates its CagA protein into epithelial cells, where it recruits 
ZO-1 and JAM-A from the TJ to adherent bacteria and disrupts TJ-mediated gate and 
 16
fence functions (2).  JAM-A thus plays key roles in the host by mediating TJ barrier 
function, inflammatory responses, angiogenesis, and interactions with pathogens.  
 
Significance of the research 
Little is known about how IgSF junction proteins function in the pathogenesis of 
the virus families that bind them.  Therefore, elucidating the role of JAM-A in reovirus 
pathogenesis might contribute to a broader understanding of the contribution of similar 
receptors in the pathogenesis of their viral ligands.  In addition, reovirus has been used in 
clinical trials for the treatment of aggressive human malignancies (123, 132).  A precise 
understanding of how reovirus-JAM-A interactions affect viral tropism could contribute 
to improved design of viral vectors for oncolytic delivery purposes. 
My work has focused on defining the role of JAM-A in reovirus pathogenesis.  I 
found that JAM-A is responsible for reovirus dissemination via the blood but is neither 
required for viral replication in the intestine nor viral access to neural routes of spread.  
This work provides evidence for the existence of one or more additional reovirus 
receptors and enhances an understanding of systemic dissemination of virus families that 
employ junction-associated IgSF members as receptors. 
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CHAPTER II 
 
JAM-A IS REQUIRED FOR EFFICIENT INFECTION OF CELLS AND SYSTEMIC 
INFECTION OF MICE BY REOVIRUS 
 
 
 
Introduction 
 JAM-A is an IgSF member that serves as a receptor for feline calicivirus (74) and 
all three serotypes of mammalian reovirus (4, 18).  Although JAM-A is the only known 
proteinaceous receptor for reovirus, nothing is known about the role of JAM-A in the 
pathogenesis of reovirus disease.  In this study, I used wild-type and isogenic JAM-A-
null mice to determine the extent to which JAM-A is required for reovirus infection of 
cells and animals.  I found that JAM-A significantly enhances but is not absolutely 
required for infection of mouse embryonic fibroblasts (MEFs).  Following peroral 
inoculation of newborn mice, I demonstrate that JAM-A is required for systemic reovirus 
infection and lethal reovirus-induced disease.  These studies confirm that JAM-A is a 
primary cellular receptor for reovirus in cultured cells and reveal a new role for JAM-A 
in systemic infection of mice. 
 
Results 
T1 and T3 reoviruses efficiently infect wild-type but not JAM-A-/- MEFs - To determine 
whether genetic deletion of JAM-A alters reovirus infection of cells, I generated primary 
MEFs from wild-type and isogenic JAM-A-/- mice and infected those cells with T1 and T3 
reovirus strains at various multiplicities of infection (MOIs).  All strains of reovirus were 
capable of infecting wild-type MEFs but not JAM-A-/- MEFs over the course of a single 
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infectious cycle (Figure II-1 A and B).  I tested the efficiency of viral replication over 
several days and found that JAM-A is required for efficient reovirus replication in MEFs 
(Figure II-1 C).  Strains T3D and T3SA+, which bind sialic acid (3, 32) replicated to higher 
titer in JAM-A-/- MEFs than did reovirus strains T1L and T3SA-, which do not bind this 
carbohydrate (3), suggesting that the capacity to bind sialic acid enhances reovirus 
infection of MEFs.  Taken together, these results demonstrate that JAM-A expression is 
required for efficient infection of MEFs by T1 and T3 reoviruses. 
 
T3D and T3SA+ reovirus infection of JAM-A-/- MEFs is reduced following 
neuraminidase treatment - To determine whether sialic acid binding mediates residual 
replication of sialic acid-binding reovirus strains in JAM-A-/- MEFs, I quantified viral 
replication following incubation of cells with a mock treatment or with Arthrobacter 
ureafaciens neuraminidase to remove cell-surface sialic acid.  T3D and T3SA+ infection 
of both wild-type and JAM-A-/- MEFs was reduced following treatment of cells with 
neuraminidase (Figure II-2).  Consistent with previous findings using HeLa cells (3), 
neuraminidase treatment did not decrease infection of wild-type or JAM-A-/- MEFs with 
T3SA- (Figure II-2).  These data indicate that reovirus T3D and T3SA+ replication in 
JAM-A-/- MEFs is in part mediated by sialic acid. 
T3 reovirus replication in JAM-A-/- MEFs may also be mediated by a receptor other 
than JAM-A or sialic acid.  To determine whether T3 reovirus replication in JAM-A-/- MEFs 
depends on σ1 head-specific interactions, I quantified viral replication following incubation 
of virus and cells with the T3 σ1 head-specific blocking monoclonal antibody (MAb) 9BG5 
(17).  Treatment with MAb 9BG5 substantially reduced infectivity of T3D, T3SA+, and  
 19
 
 
 
FIGURE II-1. JAM-A is required for efficient reovirus infection of MEFs. (A) Primary MEFs 
generated from JAM-A+/+ and JAM-A-/- embryos were adsorbed with reovirus T1L, T3D, 
T3SA-, or T3SA+ at MOIs of 0.01, 0.1, and 1 fluorescent focus unit (FFU)/cell and incubated 
for 20 hr. Reovirus antigen was detected by indirect immunofluorescence. Representative 
wells after adsorption with 1 FFU/cell are shown. (B) Infected cells were quantified in five 
fields of 200X view. Results are expressed as the mean FFU/field for triplicate experiments. 
Error bars indicate SD. *, P < 0.01 as determined by Student’s t test in comparison to JAM- 
A-/- MEFs at the same MOI. (C) Confluent monolayers of JAM-A+/+ and JAM-A-/- MEFs were 
adsorbed with reovirus T1L, T3D, T3SA-, or T3SA+ at an MOI of 2 plaque forming units 
(PFU)/cell and incubated for the times shown. Viral titers were determined by plaque assay. 
Results are expressed as mean viral yields (tx/t0) for triplicate experiments. Error bars indicate 
SD. 
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T3SA- in wild-type MEFs (Figure II-2).  Infection of JAM-A-/- MEFs with T3SA+ was 
reduced by one third with 9BG5 treatment compared to the mock-treated control (Figure II-
2).  However, infection of JAM-A-/- MEFs with T3D and T3SA- was not altered following 
9BG5 treatment.  Residual T3 reovirus infection of JAM-A-/- MEFs is therefore likely not 
mediated by T3 σ1 head-specific interactions.   
   
JAM-A is required for lethal reovirus infection following peroral inoculation - To 
determine the function of JAM-A in reovirus pathogenesis, I compared the susceptibility 
of wild-type and JAM-A-/- mice to reovirus infection and disease.  I isolated the role of 
JAM-A from the role of sialic acid in reovirus pathogenesis by using T3SA-, a reovirus 
strain incapable of binding sialic acid (3).  T3SA- spreads systemically and retains T3 
neurotropic properties (5).  Newborn wild-type and JAM-A-/- mice were inoculated 
perorally with escalating doses of T3SA-, from 10 to 109 plaque forming units (PFU), and 
survival was assessed as a function of dose.  The percentage of wild-type mice that 
succumbed to lethal encephalitis rose with increasing dose, yielding an LD50 value of 1.9 
x 107 PFU (Table II-1).  In sharp contrast, no JAM-A-/- animals succumbed to lethal 
encephalitis following inoculation with T3SA- at any dose tested (Table II-1), nor did 
JAM-A-/- mice demonstrate detectable neurological symptoms.  At the highest dose of 
T3SA- tested, 109 PFU, the majority of wild-type mice succumbed to lethal encephalitis, 
whereas all JAM-A-/- mice survived (Figure II-3 A).  As a quantitative indicator of disease 
progression, I found that surviving wild-type mice inoculated with 109 PFU gained 
weight less rapidly than similarly inoculated JAM-A-/- mice (Figure II-3 B). Taken 
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together, these results demonstrate that JAM-A is required for lethal reovirus disease 
following peroral inoculation of T3SA-. 
 
 
 
 
FIGURE II-2. Neuraminidase treatment diminishes T3 infection of JAM-A-/- MEFs. Primary 
MEFs generated from JAM-A+/+ and JAM-A-/- embryos were treated with incomplete media or 
100 mU/mL neuraminidase. Cells were adsorbed with reovirus T3D, T3SA+, or T3SA- at 
MOIs of 4 x 104 particles/cell (JAM-A+/+) or 4 x 106 particles/cell (JAM-A-/-) combined with 
incomplete medium or with 20 µg/mL 9BG5 and incubated for 20 hr. Reovirus antigen was 
detected by indirect immunofluorescence. Infected cells were quantified in five fields of 
200X view (JAM-A+/+) or five fields of 160X view (JAM-A-/-). Results are expressed as the 
mean FFU/field for triplicate experiments. Error bars indicate SD. *, P < 0.05 as determined 
by Student’s t test in comparison to mock treated MEFs. 
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TABLE II-1. JAM-A is required for T3SA- virulence following peroral inoculation a. 
 
 
Dose (PFU/mouse) JAM-A+/+ JAM-A-/- 
 Survive Succumb Survive Succumb 
10 20 0 11 0 
102 13 0   
103 14 0 15 0 
104 5 10   
105 16 4 15 0 
106 9 5   
107 13 1 14 0 
108 6 5   
109 6 20 16 0 
 
 
aNewborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with the indicated doses of 
T3SA-. Each dose was used to inoculate 2-3 litters of mice. Animals were monitored for 
survival for 21 days after inoculation, at which point survivors appeared healthy. LD50 values 
were calculated according to the method of Reed and Muench (104). The LD50 value of 
T3SA- in JAM-A+/+ mice is 1.9 x 107 PFU. The LD50 value of T3SA- in JAM-A-/- mice is > 
109 PFU. 
 
 
 
JAM-A is required for systemic reovirus replication following peroral inoculation of 
T3SA- - Although peroral inoculation of T3SA- does not cause reovirus-induced disease 
in JAM-A-/- mice, I wondered whether reovirus is capable of replication in JAM-A-/- 
animal tissues.  To determine the extent of viral replication in infected mice, I inoculated 
newborn wild-type and JAM-A-/- mice perorally with 104 PFU T3SA-, a sub-LD50 value, 
and quantified viral titer in organs at various intervals post-inoculation.  It is known that 
titers in the intestine are negligible at days 4 and 8 following peroral inoculation of 
reovirus strains that do not replicate in the intestine, such as T3D (12).  Therefore, viral 
titer in the intestine at and after 4 days post-inoculation is indicative of reovirus 
replication at that site.  Remarkably, T3SA- produced equivalent titers of virus in the 
intestine of wild-type and JAM-A-/- mice.  However, viral titers at sites of secondary  
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FIGURE II-3. T3SA- virulence is abolished following peroral inoculation of JAM-A-/- mice. 
Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 109 PFU of reovirus 
T3SA-. Mice (n = 26 JAM-A+/+ and n = 16 JAM-A-/-) were monitored for survival (A) and 
weight gain (B). *, P < 0.0001 as determined by log rank test. 
 
 
infection, including the brain, heart, liver, lung, and spleen, were substantially greater in 
wild-type animals than in JAM-A-/- mice (Figure II-4).  Thus, following peroral 
inoculation, JAM-A is dispensable for T3SA- replication in the intestine but is required 
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for production of maximal reovirus titer at sites of secondary infection, including the 
CNS.  
 
JAM-A is required for systemic reovirus replication following peroral inoculation of   
T1L - T1 and T3 reovirus strains exhibit differential tropism and disseminate via different 
routes (85, 136, 148, 149).  Since T1L does not produce uniformly lethal disease (148), 
survival studies using this strain were not possible.  Nonetheless, to determine whether 
JAM-A is required for systemic replication of a T1 reovirus strain, I inoculated wild-type 
and JAM-A-/- mice perorally with 106 PFU T1L and quantified viral titer in multiple 
organs at various intervals post-inoculation.  As with T3SA-, I found that the titer of T1L 
in the intestine of JAM-A-/- mice was similar to that in wild-type animals (Figure II-5).  
Titers of T1L at all other sites were substantially greater in wild-type animals than in 
JAM-A-/- mice.  T1L titers in the liver, lung, and spleen of JAM-A-/- animals were very 
low at 4 and 8 days post-inoculation, and, unlike T3SA-, T1L titer was absent from the 
heart and brain at all timepoints tested (Figure II-5).  Taken together, these results 
indicate that JAM-A is required for systemic infection following peroral inoculation of 
reovirus T1L. 
 
JAM-A is required for systemic reovirus replication following peroral inoculation of 
T3SA+ - Reovirus strains T3SA- and T3SA+ differ by a single amino acid polymorphism 
in σ1 that confers the capacity to bind sialic acid (3).  To determine whether JAM-A is 
required for systemic replication of a T3 reovirus strain that utilizes sialic acid as a 
receptor, I inoculated wild-type and JAM-A-/- mice perorally with 104 PFU T3SA+ and  
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FIGURE II-4. Systemic T3SA- replication is attenuated following peroral inoculation of 
JAM-A-/- mice. Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 104 
PFU T3SA-. At days 4, 8, and 12 after inoculation, mice were euthanized, organs were 
resected, and viral titers were determined by plaque assay. Each data point represents one 
animal. Horizontal bars indicate the arithmetic mean of log-transformed data. *, P < 0.05 by 
Student’s t test. 
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FIGURE II-5. Systemic T1L replication is attenuated following peroral inoculation of JAM-A-/- 
mice. Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 106 PFU T1L. At 
days 4, 8, and 12 after inoculation, mice were euthanized, organs were resected, and viral titers 
were determined by plaque assay. Each data point represents one animal. Horizontal bars indicate 
the arithmetic mean of log-transformed data. *, P < 0.05 by Student’s t test. When all values are 
less than the limit of detection, a Student’s t test P value cannot be calculated. 
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quantified viral titer at various intervals post-inoculation.  As with T3SA-, I found that 
titers of T3SA+ in the intestine of JAM-A-/- mice were similar to those in wild-type 
animals (Figure II-6).  Titers of T3SA+ at all other sites at day 8 were substantially 
greater in wild-type animals than in JAM-A-/- mice.  T3SA+ titers in the liver of JAM-A-/- 
mice are greater than T3SA- titers in the liver of JAM-A-/- mice (Figures II-4 and II-6), 
suggesting that sialic acid serves as a reovirus receptor in the mouse liver.  Unlike results 
with T3SA-, in which several JAM-A-/- animals harbored replication in the CNS, only one 
JAM-A-/- animal at each timepoint displayed T3SA+ titers in the brain.  These results 
demonstrate that JAM-A is required for systemic infection following peroral inoculation 
of T3SA+.  Thus, JAM-A is a requirement for systemic infection of both T1 and T3 
reoviruses. 
 
Discussion 
In this chapter, I present data indicating that genetic deletion of JAM-A in 
fibroblast cells results in a 100- to 1,000-fold decrease in reovirus infectivity and 
replication.  I demonstrate further that the residual T3 reovirus infection of JAM-A-null 
fibroblasts is at least in part due to reovirus interactions with cell-surface sialic acid.  
However, these data also indicate that some reovirus infection of JAM-A-/- MEFs is 
mediated neither by host cell sialic acid nor by the viral 9BG5-binding region of the T3 
σ1 head.  Although JAM-A is the only proteinaceous receptor known to bind to the 
reovirus σ1 head domain, it is plausible that reovirus infection of some types of cells 
occurs via interactions with receptors that bind regions of reovirus σ1 outside the 9BG5- 
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FIGURE II-6. Systemic T3SA+ replication is attenuated following peroral inoculation of 
JAM-A-/- mice. Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 104 
PFU T3SA+. At days 4, 8, and 12 after inoculation, mice were euthanized, organs were 
resected, and viral titers were determined by plaque assay. Each data point represents one 
animal. Horizontal bars indicate the arithmetic mean of log-transformed data. *, P < 0.05 by 
Student’s t test. When all values are less than the limit of detection, a Student’s t test P value 
cannot be calculated. 
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binding area or other exposed viral proteins.  It is also possible that reovirus infection of 
cells occurs via a receptor-independent uptake mechanism.  
By virtue of their capacity to infect the intestine and spread systemically to the 
CNS, reoviruses offer an ideal experimental system to define how neurotropic viruses 
interact with their hosts at different steps during the disease process.  Following peroral 
inoculation, reovirus T3SA- interactions with JAM-A are required for replication in 
target organs and production of lethal encephalitis but surprisingly dispensable for 
intestinal replication.  Similarly, JAM-A is also required for systemic replication of both 
T1L and T3SA+ reovirus strains.  These results indicate that JAM-A serves to promote 
systemic infection of reovirus in a serotype-independent manner. 
A striking finding of these studies is that genetic deletion of JAM-A does not 
influence the capacity of reovirus to replicate in the intestine following peroral 
inoculation.  This is true for the T3SA-, T3SA+, and T1L strains of reovirus.  Previous 
work has demonstrated that the capacity to bind sialic acid does not influence reovirus 
replication in the intestine following peroral inoculation (5).  Therefore, neither JAM-A 
nor sialic acid is likely the cellular ligand that mediates reovirus replication in the mouse 
intestine.  Since both T1 and T3 reovirus strains can replicate in the intestine of JAM-A-/- 
mice, it is likely that reovirus infection at that site is mediated by a serotype-independent 
receptor or a receptor-independent uptake mechanism. 
Whereas T1 and T3 reoviruses replicate to high titer in the intestine of both wild-
type and JAM-A-/- mice, replication at extra-intestinal sites is severely curtailed in JAM-
A-null mice in comparison to wild-type mice.  I envision two possible explanations for 
this finding.  First, JAM-A might be required for replication in target organs.  In this case, 
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JAM-A would be the primary reovirus receptor at sites outside the intestine, whereas an 
unknown serotype-independent receptor or a receptor-independent uptake mechanism 
would mediate reovirus replication in the intestine.  Second, JAM-A might be required 
for dissemination from the intestine to target organs.  Since reovirus can disseminate 
neurally, hematogenously, or via both pathways, in this scenario JAM-A would be 
required for reovirus dissemination via one or both of these routes.  By circumventing 
dissemination pathways altogether, intracranial inoculation experiments using wild-type 
JAM-A-/- mice are required to discriminate between these possibilities. 
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CHAPTER III 
 
JAM-A IS NOT REQUIRED FOR REOVIRUS INFECTION OF NEURONS  
OR TROPISM WITHIN THE CNS 
 
 
 
Introduction 
In Chapter II, I describe work demonstrating that JAM-A is not required for 
reovirus replication in the intestine but is required for systemic replication of reovirus.  I 
thought it possible that reovirus might be incapable of either dissemination to sites of 
secondary infection in JAM-A-/- mice or establishing infection once reaching those sites.  
To distinguish between these possibilities, I inoculated wild-type and isogenic JAM-A-
null mice intracranially.   I found that JAM-A is not required for reovirus virulence or 
replication in the CNS following intracranial inoculation.  I also found that JAM-A is not 
required for T3 reovirus tropism for neurons in the cortex, hippocampus, thalamus, and 
cerebellar Purkinje cells.  Further, JAM-A is not required for reovirus infection of 
primary cortical neurons in vitro.  Together with findings from Chapter II, these results 
reveal a role for JAM-A in systemic dissemination of reovirus and provide evidence for 
the existence of a neural-specific T3 reovirus receptor. 
Some of the research described in this chapter was performed in collaboration 
with other investigators.  Dr. Ty Abel (Department of Pathology at the Vanderbilt 
University School of Medicine) guided the histologic analyses of brain sections and 
captured representative images.  Ana Perdigoto and Dr. Bruce Carter (Department of 
Biochemistry and Center for Molecular Neuroscience at the Vanderbilt University School 
of Medicine) aided in the extraction and culture of primary cortical neurons from wild-
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type and JAM-A-/- mouse embryos.  Dr. Jennifer Konopka (Department of Pediatrics at 
the Vanderbilt University School of Medicine) and Johnna Allen (Department of 
Microbiology & Immunology at the Vanderbilt University School of Medicine) assisted 
in the extraction and culture of mouse cortical neuron cultures.  Dr. Konopka and I 
contributed equally to the cortical neuron studies presented here.  In addition, Dr. 
Konopka performed the blinded analysis of histologic sections presented in Table III-2. 
 
Results 
JAM-A is not required for lethal reovirus infection following intracranial inoculation - To 
determine whether JAM-A is required for reovirus virulence once virus accesses the 
brain, I inoculated wild-type and JAM-A-/- mice intracranially with escalating doses of 
reovirus T3SA- and assessed survival as a function of dose.  Both wild-type and JAM-A-/- 
mice succumbed to lethal encephalitis, yielding similar LD50 values (Table III-1).  At a 
dose of 100 PFU T3SA- delivered intracranially, wild-type and JAM-A-/- mice alike 
succumbed to lethal reovirus-induced disease (Figure III-1 A).  Alterations in weight gain 
following infection of the two genotypes were equivalent (Figure III-1 B).  These results 
indicate that reovirus is fully virulent following direct inoculation into the brain of JAM-
A-/- mice and suggest a role for JAM-A in systemic dissemination of reovirus from the 
intestine. 
 
JAM-A is not required for T1 and T3 reovirus replication in the brain following 
intracranial inoculation - Following peroral inoculation, JAM-A is required for systemic 
replication of both T1 and T3 reovirus strains (Figures II-4, II-5, and II-6).  In particular,  
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TABLE III-1. JAM-A is dispensable for T3SA- virulence following intracranial inoculationa 
 
 
Dose (PFU/mouse) JAM-A+/+ JAM-A-/- 
 Survive Succumb Survive Succumb 
1 17 0 16 0 
10 10 1 11 3 
102 9 31 5 27 
103 1 21 0 14 
104 0 16 0 13 
 
 
aNewborn JAM-A+/+ and JAM-A-/- mice were inoculated intracranially with the indicated 
doses of T3SA-. Each dose was used to inoculate 2-3 litters of mice. Animals were monitored 
for survival for 21 days after inoculation, at which point survivors appeared healthy. LD50 
values were calculated according to the method of Reed and Muench (104). The LD50 value 
of T3SA- in wild-type mice is 52 PFU. The LD50 value of T3SA- in JAM-A-/- mice is 41 PFU. 
 
 
 
replication of T1 and T3 reovirus strains in the brain of JAM-A-/- mice following peroral 
inoculation is diminished in comparison to that in wild-type animals.  To determine 
whether JAM-A is required for reovirus replication in the brain, I inoculated wild-type 
and JAM-A-/- mice intracranially with 100 PFU T3SA- or 103 PFU T1L and quantified 
viral titer in brain homogenates at various intervals post-inoculation.  I found that T3SA- 
and T1L reached equivalent or higher titers in the brain of JAM-A-/- mice in comparison 
to those in wild-type mice following intracranial inoculation (Figure III-2).  These results 
indicate that murine CNS tissue is capable of supporting T1L and T3SA- reovirus 
infection regardless of JAM-A expression. 
To determine whether sialic acid-binding T3 reovirus strains can replicate in JAM-
A-/- CNS tissue, I inoculated wild-type and JAM-A-/- mice perorally with 100 PFU of 
either T3D or T3SA+ and quantified viral titer in brain homogenates.  I found that 
T3SA+ reached equivalent or higher titer in the brain of JAM-A-/- mice in comparison to  
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FIGURE III-1. T3SA- is fully virulent following intracranial inoculation of JAM-A-/- mice. 
Newborn JAM-A+/+ and JAM-A-/- mice were inoculated intracranially with 100 PFU of 
reovirus T3SA-. Mice (n = 15 JAM-A+/+ and n = 13 JAM-A-/-) were monitored for survival 
(A) and weight gain (B). Survival P value > 0.05 as determined by log rank test. 
 
 
 
that in wild-type mice following intracranial inoculation (Figure III-2).  However, T3D 
replicated somewhat less efficiently in JAM-A-/- mouse brain compared to wild-type 
mouse brain (Figure III-2).  These results indicate that sialic acid-binding T3 reovirus 
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strains can replicate to high titers in the brain of JAM-A-/- animals.  Taken together with 
results from Chapter II, these data indicate that JAM-A is required for systemic 
dissemination of T1 and T3 reovirus strains from the intestine. 
 
 
 
 
FIGURE III-2. Reovirus replicates to high titer in the brains of JAM-A-/- mice. Newborn 
JAM-A+/+ and JAM-A-/- mice were inoculated intracranially with 100 PFU T3SA-, 103 PFU 
T1L, 100 PFU T3SA+, or 100 PFU T3D. At days 4, 8, 10, and 12 after inoculation, mice 
were euthanized, brains were resected, and viral titers were determined by plaque assay. Each 
data point represents one animal. Horizontal bars indicate the arithmetic mean of log-
transformed data. *, P < 0.05 by Student’s t test. 
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T3 reovirus regional tropism in the brain is not altered in JAM-A-/- mice - The σ1-encoding 
S1 gene of reovirus is the main determinant of viral tropism within the CNS (81, 86, 148, 
150).  To test whether σ1-JAM-A interactions are required for the distinct regional tropism 
of T3 reovirus, I compared histologic sections of brain from wild-type and JAM-A-/- mice 
inoculated intracranially with 104 PFU T3SA-.  Brains of infected mice were resected and 
bisected sagittally.  The left hemisphere was prepared for viral titer determination by 
plaque assay, and the right hemisphere was processed for histopathology.  Brain sections 
chosen for histologic analysis were matched for hippocampal depth and viral titer.  
Hematoxylin and eosin (H&E)-stained sections showed a consistent pattern of injury in 
both wild-type and JAM-A-/- mice.  In both mouse strains, neurons of the hippocampal 
pyramidal layers were affected, showing abundant eosinophilic, cytoplasmic inclusions 
and individual cell necrosis and apoptosis.  Similar changes were observed in cerebellar 
Purkinje layer neurons, with relative sparing of granule cells.  Other regions consistently 
affected in both strains of mice included the dorsal thalamic nuclei, hypothalamus, and 
middle layers of the cerebral cortex (Figure III-3).  Immunohistochemistry for reovirus 
antigen confirmed the presence of virus in hippocampal and cerebellar neurons and cells 
with neuronal morphology in other affected regions (Figure III-3).  Ependymal cells were 
spared in both genotypes of mice.  The reovirus antigen signal appeared more intense in 
the cortex, especially the outer layers, and the hippocampus of JAM-A-/- brain when 
compared to wild-type brain.  To quantify this observation, we performed a blinded 
analysis of brain sections matched for hippocampal depth and viral titer and found that a 
greater percentage of cells in both the middle and outer layers of cells of the cortex 
displayed reovirus antigen in JAM-A-/- mice compared to wild-type (Table III-2).  
 37
However, reovirus targeted the same cell types and brain regions in both mouse strains.  
These data indicate that JAM-A is not the primary cellular factor mediating the unique 
targeting of T3 reovirus to specific regions within the brain. 
 
Reovirus infection of mouse cortical cultures does not depend on JAM-A - To directly test 
whether JAM-A is required for reovirus infection of neurons, I infected primary cortical 
neuron cultures prepared from embryonic wild-type and JAM-A-/- mice with T1 and T3 
reovirus strains.  The cortical neurons displayed classic neuronal morphology and stained 
for the neuron-specific beta III tubulin marker, TUJ1.  The pattern of T3 reovirus antigen 
staining was identical in wild-type and JAM-A-/- cortical neurons, which displayed similar 
morphology and characteristics of reovirus infection (Figure III-4 A).  In both types of 
neurons, reovirus-positive inclusions were observed dotting the length of infected axons, 
a staining pattern consistent with focal sites of reovirus replication (9).  T3D replication 
in neurons was equivalent in wild-type and JAM-A-/- cultures (Figure III-4 B).  T1L 
replicated less than T3D in mouse cortical neurons (Figure III-4 B), consistent with 
previous observations (35).  Replication of T3SA- and T3SA+ was diminished in JAM-A-/- 
neuron cultures compared to wild-type at 24 hours but was equivalent to wild-type by 48 
hours post-infection.  Thus, JAM-A is dispensable for neural infection of T3 reovirus 
strains.  
 
T3 reovirus infection of primary cortical neurons is reduced following treatment with 
neuraminidase and σ1 antibody - To determine whether sialic acid binding mediates viral 
replication in primary cortical neurons, I assessed reovirus infection at 20 h following  
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FIGURE III-3. JAM-A is dispensable for T3SA- tropism within the brain. Newborn JAM-
A+/+ and JAM-A-/- mice were inoculated intracranially with 104 PFU T3SA-. Eight days after 
inoculation, brains of infected mice were resected and bisected sagittally. The left hemisphere 
was prepared for viral titer determination by plaque assay, and the right hemisphere was 
processed for histopathology. Consecutive coronal sections were stained with H&E or 
polyclonal reovirus antiserum. Representative sections of brain hemisphere (A), matched for 
hippocampal depth, and cerebellum (B) are shown. Boxes indicate areas of enlargement in 
the panels on the right and show cortical neurons (A) and cerebellar Purkinje neurons (B). 
JAM-A+/+ brain sections are from brains with left hemisphere viral titers of 4.1 x 109 PFU (A) 
and 3.0 x 109 (B). JAM-A-/- brain sections are from brains with left hemisphere viral titers of 
3.4 x 109 PFU (A) and 1.6 x 109 PFU (B).  
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TABLE III-2. JAM-A deletion alters the reovirus antigen staining intensity in the cortex following intracranial inoculationa 
 
 
Cortical Layer Hippocampal Region Genotype Viral Titer 
Middle Outer CA 1 CA 2-4 
Thalamus Cerebellar Purkinje Layer 
JAM-A+/+ 9.53 2 1 1 2 4 5 
 9.61 3 1 1 2 4 2 
 9.48 1 0 1 2 3 4 
 9.49      4 
 9.75      4 
Group mean 9.57 2 0.67 1 2 3.67 3.8 
        
JAM-A-/- 9.02 5 4 2 4 4 1 
 9.48 5 3 1 2 2 3 
 9.60 5 5 3 4 5 5 
 8.89 3 3 1 3 1 1 
 9.53 4 3 4 4 2 1 
 9.19      2 
Group mean 9.28 4.4 3.6 2.2 3.4 2.8 2.17 
 P > 0.05 P < 0.05 P < 0.05 # # P > 0.05 P > 0.05 
 
aNewborn JAM-A+/+ and JAM-A-/- mice were inoculated intracranially with 104 PFU T3SA-. Eight days after inoculation, brains of infected 
mice were resected and bisected sagittally. The left hemisphere was prepared for viral titer determination by plaque assay, and the right 
hemisphere was processed for histopathology. Brain sections chosen for histologic analysis were matched for hippocampal depth. The 
researcher was blinded to the genotype of the brain section and scored each region according to the following scale: 0 indicates no reovirus 
antigen staining, 1 indicates 1-20% of cells in the indicated region display reovirus antigen staining, 2 indicates 21-40% of cells in the 
indicated region display reovirus antigen staining, 3 indicates 41-60% of cells in the indicated region display reovirus antigen staining, 4 
indicates 61-80% of cells in the indicated region display reovirus antigen staining, and 5 indicates 81-100% of cells in the indicated region 
display reovirus antigen staining. When sections matched for hippocampal depth were not available for an animal, that animal was not 
included in the analysis. P values compare the JAM-A+/+ group to the JAM-A-/- group and were calculated by Student’s t test. # indicates that a 
Student’s t test P value cannot be calculated because all values are identical for one group. 
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either mock treatment or treatment with A. ureafaciens neuraminidase to remove cell-
surface sialic acid.  T3 reovirus strains infected the primary neurons, whereas T1L 
infection was minimal, consistent with previous reports (35).  T3D and T3SA+ infection of 
both wild-type and JAM-A-/- neurons was reduced following treatment of cells with 
neuraminidase (Figure III-5).  Consistent with previous findings using HeLa cells (3) and 
MEFs (Figure II-2), neuraminidase treatment did not decrease infection of primary neurons 
with T3SA- (Figure III-5).  T3SA+ infection of neural cultures in the untreated condition 
was approximately three-fold higher than that of T3SA- (Figure III-5).  These data indicate 
that T3D and T3SA+ reovirus replication in primary neurons is in part mediated by sialic 
acid. 
The capacity of reovirus to replicate in primary neurons is mediated by the S1 gene, 
but the only known reovirus receptor that binds the σ1 head, JAM-A, is not responsible for 
mediating reovirus infection of neurons (Figure III-4).  It is possible that other cellular 
receptors also bind this σ1 domain.  To determine whether T3 reovirus replication in 
primary neurons depends on interactions of the σ1 head with the cell surface, I assessed 
virus replication following incubation of virus and cells with the T3 σ1 head-specific MAb 
9BG5 (17) and the T1 σ1 head-specific MAb 5C6 (142).  Treatment with MAb 9BG5 
substantially reduced infectivity of T3D and T3SA- reovirus strains in primary neurons 
(Figure III-5).  T1L did not infect primary neurons regardless of treatment (Figure III-5).  
These data suggest that T3 reovirus infection of primary cortical neurons is mediated by a 
σ1 head-specific receptor other than JAM-A.   
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FIGURE III-4. JAM-A is not required for reovirus replication in primary cortical neurons. 
Cortices were isolated from day E15 JAM-A+/+ and JAM-A-/- mice and cultured in vitro for 5 
to 7 days. (A) Cells were infected with reovirus T3D at an MOI of 103 PFU/cell. At 20 h 
post-infection, cells were fixed with methanol and stained with TUJ1 neural-specific marker 
to detect neurons (red), DAPI stain to detect nuclei (blue), and polyclonal reovirus antiserum 
to detect reovirus antigen (green). (B) Cells (2 x 105) were adsorbed with T1L or T3D at an 
MOI of 10 PFU/cell. Titers of virus in cell lysates at the indicated intervals post-infection 
were determined by plaque assay. Results are expressed as viral yields for triplicate samples. 
Error bars indicate SD. 
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Discussion 
Systemic virus infections are characterized by replication at the entry site 
followed by dissemination to and replication within target organs (137).  In Chapter II, I 
present data indicating that reovirus interactions with JAM-A are required for replication 
in target organs and production of encephalitis but surprisingly dispensable for 
replication in the intestine.  Here, I demonstrate that failure of reovirus to cause 
encephalitis in JAM-A-/- mice following peroral inoculation is not due to an intrinsic 
block to reovirus replication in JAM-A-/- neural tissues.  Rather, JAM-A expression is 
required for efficient T1 and T3 reovirus dissemination in the host. 
That JAM-A is not required for reovirus T3SA- replication in the brain suggests the 
existence of novel receptors for reovirus at this site.  Analysis of histologic brain sections 
provides corroborating evidence indicating that T3SA- regional tropism within the CNS 
does not depend on JAM-A and is identical to the regional tropism of a sialic acid-
binding T3 reovirus strain inoculated intracranially into wild-type mice (105).  
Furthermore, genetic deletion of JAM-A does not alter reovirus infection of primary 
cultures of neurons.  These data provide strong evidence that reovirus interactions with 
neurons are mediated by a currently unknown serotype-specific receptor other than JAM-
A or sialic acid. 
Genetic deletion of JAM-A does not substantially alter the unique pattern of T3 
reovirus tropism within the murine brain nor does it prevent the T1 and T3 reovirus 
strains tested here from replicating to high titer in the brains of mice.  However, there 
exist subtle differences in reovirus tropism and replication in the two mouse strains.  For 
example, T3 reovirus antigen staining is greater in the outer layers of the cortex of JAM-A-/-  
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FIGURE III-5. Neuraminidase treatment and σ1 antibody inhibit T3 infection of murine 
primary cortical cultures. Primary cortical cultures generated from JAM-A+/+ and JAM-A-/- 
embryos were treated with incomplete media or 40 mU/mL neuraminidase for 1 h. Reovirus 
T1L was incubated with incomplete medium or 50 µg/mL 5C6 for 1 h. T3D, T3SA-, and 
T3SA+ were incubated with incomplete medium or 50 µg/mL 9BG5 for 1 h. Cells were 
adsorbed with reovirus at an MOI of 103 virus particles/cell and incubated for 20 h. Reovirus 
antigen and DAPI stain for nuclei were detected by indirect immunofluorescence. Total 
nuclei and infected cells were quantified in three fields of 200X view. Results are expressed 
as the mean percent infected cells/field for triplicate experiments. Error bars indicate SD. 
Within each condition, the JAM-A+/+ and JAM-A-/- means are equivalent by Student’s t test. *, 
P < 0.05 as determined by Student’s t test compared to the genotype’s mock condition. 
 
 
 
mouse brains than in wild-type brains.  Also, T1L brain replication is 10-50 fold greater 
following intracranial inoculation in JAM-A-/- mouse brains than wild-type brains.  It is 
possible that the absence of JAM-A results in alterations in expression of other reovirus 
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receptors in regions of JAM-A-/- mouse brains.  In support of this idea, overexpression of 
dimerization-defective JAM-A mutants in 293T cells results in diminished β1 integrin 
expression (116). 
In this chapter, I report that JAM-A is not required for T3SA- or T1L replication in 
the brain following intracranial inoculation, for the unique CNS tropism of T3SA-, or for 
T1 or T3 replication within primary neurons.  These results, coupled with those presented 
in Chapter II, indicate that JAM-A is required for dissemination of reovirus from the 
intestine to target organs such as the brain.    
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CHAPTER IV 
 
JAM-A IS REQUIRED FOR HEMATOGENOUS DISSEMINATION OF REOVIRUS 
 
 
 
Introduction 
Findings presented in Chapter II demonstrate that JAM-A is not required for 
reovirus growth in the intestine but is required for systemic replication of reovirus.  In 
addition, work presented in Chapter III indicates that reovirus replication in the CNS is 
not dependent on JAM-A following intracranial inoculation, suggesting that JAM-A is 
required for efficient dissemination of reovirus from the intestine to target organs such as 
the brain.  In newborn mice, reovirus can disseminate neurally or hematogenously, 
depending on the strain of reovirus and the route of inoculation.  It was unknown whether 
JAM-A mediates neural, hematogenous, or both routes of dissemination. 
 In this study, I inoculated wild-type and isogenic JAM-A-null mice perorally and 
in the hindlimb and determined the extent to which JAM-A is required for reovirus 
replication in lymphatic tissue, establishment of viremia, and neural spread to the CNS.  I 
found that JAM-A is not required for neural dissemination to the spinal cord, suggesting 
a role for JAM-A in mediating hematogenous dissemination.  Indeed, JAM-A is required 
for infection of primary endothelial cells and establishment of high levels of reovirus 
viremia.  These results provide strong evidence indicating that JAM-A is required for 
reovirus dissemination within the bloodstream. 
Some of the research described in this chapter was performed in collaboration 
with other investigators.  Dr. Ty Abel (Department of Pathology at the Vanderbilt 
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University School of Medicine) captured representative images of intestine.  Dr. Ambra 
Pozzi (Departments of Cancer Biology and Medicine at the Vanderbilt University School 
of Medicine and Department of Medicine at the Nashville Veteran Affairs Hospital) 
guided the extraction and culture of primary murine lung endothelial cells. 
 
Results 
JAM-A promotes hematogenous but not neural spread of reovirus from the hindlimb to 
the spinal cord - Following inoculation into the hindlimb, section of the sciatic nerve 
ablates spread of strain T3D but not T1L to the inferior spinal cord (ISC), indicating that 
T3D spreads neurally to the spinal cord, whereas T1L spreads primarily hematogenously to 
that site (136).  To determine the mechanism by which JAM-A promotes reovirus 
dissemination, we inoculated wild-type and JAM-A-/- mice into the hindlimb with 106 PFU 
of either T1L or T3D and quantified viral titer in the hindlimb, blood, and ISC.  After 
inoculation with T3D, both wild-type and JAM-A-/- mice harbored high viral titers in the 
ISC and low titers in the blood, consistent with an intact neural route of spread (Figure IV-
1 A).  The ratio of T3D titer in the ISC to that in the hindlimb in wild-type and JAM-A-/- 
mice was equivalent at 2, 4, and 6 days post-inoculation, indicating that spread from 
hindlimb to ISC in both genotypes is intact at those times (Figure IV-1 B).  On day 8, the 
ratio of T3D titer in the ISC to that in the hindlimb in JAM-A-/- mice is lower than that in 
wild-type mice (Figure IV-1 B), perhaps reflecting accelerated clearance of T3D in the 
spinal cord of JAM-A-/- mice in comparison to wild-type animals.  After inoculation of T1L 
into wild-type mice, titers in blood and ISC increased virtually simultaneously over the 
experimental timecourse, consistent with a hematogenous route of spread (Figure IV-1 A).   
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FIGURE IV-1. Following hindlimb inoculation, JAM-A is required for efficient 
hematogenous but not neural spread of reovirus. (A-B) Newborn JAM-A+/+ and JAM-A-/- mice 
were inoculated into the left hindlimb with 106 PFU of either T3D or T1L. At days 2, 4, 6, 
and 8 after inoculation, mice were euthanized and left hindlimb, blood, and inferior spinal 
cord (ISC), including the thoracic and lumbosacral cord segments, were resected. Viral titers 
were determined by plaque assay. Results are expressed as mean viral titers (A) or as a ratio 
of ISC viral titer to hindlimb viral titer (B) for 6 animals for each time point. Error bars 
indicate SD. *, P < 0.05 by Student’s t test. 
 
 
 48
In contrast, the titer of T1L in blood and ISC in JAM-A-/- mice increased with markedly 
reduced kinetics in comparison to the titer rise in wild-type animals (Figure IV-1 A).  The 
ratio of T1L titer in the ISC to that in the hindlimb in wild-type mice is greater than that in 
JAM-A-/- mice at 2, 4, and 6 days post-inoculation, indicating that spread of T1L from 
hindlimb to ISC is blunted in JAM-A-/- mice (Figure IV-1 B).  These findings suggest that 
JAM-A is an important mediator of hematogenous but not neural dissemination of reovirus 
from the hindlimb.  
 
Reovirus T1L targets intestinal epithelial cells and Peyer’s patches regardless of JAM-A 
expression - To confirm that JAM-A is required for T1L reovirus replication in the 
intestine, we compared histologic sections of intestines from wild-type and JAM-A-/- mice 
inoculated perorally with 108 PFU of T1L.  In both mouse strains, epithelial cells of small 
intestinal villi were infected at early times post-inoculation and showed abundant 
eosinophilic, cytoplasmic inclusions (Figure IV-2 A).  Immunohistochemistry for 
reovirus antigen confirmed the presence of virus in villus epithelial cells (Figure IV-2 A).  
Mononuclear cells within Peyer’s patches also displayed reovirus antigen (Figure IV-2 
B).  These results indicate that reovirus T1L replication in intestinal epithelial cells and 
intestinal lymphatic tissue is independent of JAM-A. 
 
Reovirus dissemination to lymphatic tissues is diminished but not abolished in JAM-A-/- 
animals - Following peroral inoculation and localization to Peyer’s patches, reovirus T1L 
disseminates to mesenteric lymph nodes (MLNs) and spleen within 24 h (61).  To 
determine whether JAM-A is required for lymphatic or bloodstream dissemination, we 
inoculated wild-type and JAM-A-/- mice perorally with 108 PFU of T1L and quantified viral  
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FIGURE IV-2. JAM-A is dispensable for tropism of reovirus T1L within the intestine. (A-B) 
Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 108 PFU of T1L. At 
days 2 and 4 after inoculation, small intestines were resected and processed for 
histopathology. Consecutive sections were stained with H&E or polyclonal reovirus 
antiserum. Representative sections of intestinal villi at day 2 (A) and Peyer’s patches (PP) at 
day 4 (B) are shown. Boxes indicate areas of enlargement in the panels on the right and show 
villus epithelial cells. 
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titer in the MLN, spleen, and blood.  In both wild-type and JAM-A-/- mice, viral titer in the 
MLN and spleen were detectable at early times post-inoculation and increased over the 
course of infection, although T1L produced greater titers in wild-type versus JAM-A-/- mice 
(Figure IV-3).  The titer of T1L in the blood of wild-type mice was detectable by day 2 
post-inoculation and increased thereafter (Figure IV-3).  In sharp contrast, with the 
exception of one animal per timepoint, there was no detectable titer of T1L in the blood of 
JAM-A-/- mice (Figure IV-3).  Similar results were obtained in experiments using T3SA- 
(Figure IV-4).  Therefore, JAM-A is not required for access to lymphatic routes of 
dissemination but is required for the establishment of high titer viremia following peroral 
inoculation of reovirus. 
 
 
 
 
FIGURE IV-3. JAM-A is not required for reovirus dissemination to lymphatic tissue. 
Newborn JAM-A+/+ and JAM-A-/- mice were inoculated perorally with 108 PFU of T1L. At 
days 1, 2, 4, and 6 after inoculation, mice were euthanized, mesenteric lymph node (MLN), 
blood, and spleen were collected, and viral titers were determined by plaque assay. Results 
are expressed as mean viral titers for 3-8 animals for each time point. Error bars indicate SD. 
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FIGURE IV-4. JAM-A is required for high-titer reovirus viremia. Newborn JAM-A+/+ and 
JAM-A-/- mice were inoculated perorally with 108 PFU of T3SA- (top), 106 PFU of T3SA- 
(middle), or 106 PFU of T1L (bottom). At days 4 and 8, mice were euthanized, blood was 
collected, and viral titer in the blood was determined by plaque assay. Each data point 
represents one animal. Horizontal bars indicate the arithmetic mean of log-transformed data. 
*, P < 0.05 by Student’s t test. When all values are less than the limit of detection (T3SA- 106 
day 8, T1L day 4 and day 8 in JAM-A-/- mice), a Student’s t test P value cannot be calculated.  
 
 52
JAM-A is required for efficient infection of primary endothelial cells – Endothelial cells 
(ECs) line blood vessels and serve as portals for virus entry into the circulation (90).  To 
test whether JAM-A is required for reovirus infection of ECs, we infected primary mouse 
lung endothelial cells prepared from adult wild-type and JAM-A-/- mice with T1L and 
T3SA-.  The ECs displayed classic cobblestone morphology (Figure IV-5 A) and differed 
in JAM-A expression (Figure IV-5 B).  Both strains of reovirus were capable of infecting 
wild-type but not JAM-A-/- ECs over the course of a single infectious cycle (Figures IV-5 C 
and D).  These results indicate that JAM-A expression is required for efficient infection of 
mouse ECs by reovirus. 
 
Discussion 
Reovirus strains disseminate systemically via hematogenous, neural, or a 
combination of both routes (44, 61, 85, 136).  Spread of T3D from hindlimb to spinal 
cord, which occurs by neural routes (136), is not dependent on JAM-A.  In contrast, 
spread of T1L from hindlimb to spinal cord, which occurs by hematogenous routes (136), 
is markedly diminished in JAM-A-/- animals in comparison to wild-type controls.  
Additionally, primary neurons isolated from wild-type and JAM-A-/- mice are equivalently 
susceptible to reovirus infection.  These findings indicate that JAM-A mediates 
hematogenous but not neural dissemination of reovirus.  
Viruses can establish viremia by several different mechanisms, including transport 
through lymphatics, infection of endothelial cells, and infection of blood leukocytes (90).  
However, mechanisms of reovirus viremia are unknown.  Titers of T1L and T3SA- in the 
blood are diminished or undetectable in all JAM-A-/- mice following peroral inoculation.   
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FIGURE IV-5. JAM-A is required for infection of primary endothelial cells. (A-B) Primary 
endothelial cells generated from JAM-A+/+ and JAM-A-/- mice were adsorbed with either 
reovirus T1L or T3SA- at MOIs of 1, 10, and 100 PFU/cell and incubated for 20 hr. Cells 
were stained with polyclonal reovirus antiserum to detect reovirus antigen (green) and 4’6-
diamidino-2-phenylindole (DAPI) to detect nuclei (blue) and visualized using indirect 
immunofluorescence microscopy. Representative fields of view from triplicate experiments 
using an MOI of 100 PFU/cell are shown (A). The percentage of infected cells was quantified 
by dividing the number of cells exhibiting reovirus staining by the total number of cell nuclei 
exhibiting DAPI staining in entire wells of 96-well plates for triplicate experiments (B). 
Wells contained between 200 and 1600 nuclei. Error bars indicate SD. *, P < 0.05 as 
determined by Student’s t test in comparison to JAM-A-/- endothelial cells at the same MOI. 
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Nevertheless, both strains of reovirus are capable of reaching the spleen in JAM-A-/- mice 
following peroral inoculation, albeit in diminished titers in comparison to those in wild-
type animals.  Since the only hematogenous pathway from the intestine to the spleen is via 
the blood, the presence of virus in the spleen of JAM-A-/- mice following peroral 
inoculation indicates that some virus likely escapes into the bloodstream in these animals, 
although viremic titer is reduced below the limit of detection in most JAM-A-/- animals.  
Lymphatic spread of T1L from intestine to MLN is diminished but not abolished in JAM-A-
/- animals in comparison to wt animals.  Most strikingly, JAM-A is required for infection of 
primary endothelial cells.  Thus, two important routes to the establishment of viremia – 
spread through lymphatics and infection of endothelial cells - are impaired in JAM-A-/- 
animals. 
TJs of the intestinal mucosa of JAM-A-/- mice demonstrate normal expression of 
occludin and claudin-2, upregulation of claudin-10 and claudin-15, and increased 
permeability to small molecules but not bacteria (70).  Alterations in the ratios of claudin-
10 and claudin-15 can affect the permeability of the epithelium to small molecules (130, 
138), but the normal expression of TJ structural proteins such as occludin, zonula 
occludens-1, and E-cadherin (75) suggests that the absence of JAM-A does not lead to 
overt changes in TJ structure or assembly (70).  Reovirus virions are ~ 25,000 times 
larger than the small molecules used in the permeability experiments reported previously 
(70) and roughly the size of a TJ.  Therefore, I do not think the absence of JAM-A leads 
to the free flux of reovirus between intestinal epithelium and underlying tissue.  This 
conclusion is supported by intestinal micrographs demonstrating that the absence of 
JAM-A does not alter the histologic pattern of reovirus intestinal infection.  Moreover, 
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any alterations in the permeability of JAM-A-/- intercellular junctions do not enhance the 
capacity of reovirus to access the lymphatic circulation and the bloodstream following 
replication in the intestine.  Instead, my results indicate that specific interactions of 
reovirus with JAM-A promote hematogenous dissemination. 
In this chapter, I report that JAM-A is not required for neural dissemination of T3D 
from the hindlimb but is required to establish reovirus viremia and to reach peak titers in 
lymphatic tissues.  These results, together with those presented in Chapters II and III, 
indicate that JAM-A mediates hematogenous dissemination of reovirus. 
 56
CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 Virus attachment to cells is mediated by discrete cellular receptors, many of 
which are members of the IgSF.  JAM-A is one such IgSF molecule and is the only 
identified proteinaceous receptor for reovirus (4).  Although the atomic details of 
reovirus-JAM-A interactions have been elucidated, little is known about how JAM-A 
mediates reovirus infection in vivo.  The goal of my dissertation research was to 
determine the role of JAM-A in reovirus pathogenesis.  Findings presented in this thesis 
provide evidence that JAM-A mediates hematogenous dissemination of reovirus.  This 
chapter summarizes the findings presented herein, integrates the findings with what is 
understood about other IgSF virus receptors, and provides insights into future directions 
for this research. 
 
Mechanisms of establishment of viremia 
Viruses disseminate systemically either in the bloodstream, via nerves, or using a 
combination of both routes.  Viremia is established through one or more sites, including 
efferent lymphatics, vascular endothelium, and peripheral blood leukocytes.  Viruses that 
access the bloodstream via lymphatics do so by transiting from the site of entry through 
afferent lymphatic vessels, regional lymph nodes, efferent lymphatic vessels, and the 
thoracic duct, which connects the lymphatic system to the blood circulatory system.  
Viremia is often preceded by replication within regional lymph nodes, but passive 
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transport of virus from the entry site through lymphatics to the bloodstream can be 
achieved without viral replication within lymphatic nodes (90).   
 Several viruses access the bloodstream via the vascular endothelium.  Infection 
of, transit between, and transcytosis through lymphatic and blood endothelial cells afford 
viral passage from infected tissue to the circulation.  Infection of endothelial cells 
generates the majority of viral load found in the bloodstream 48 hours following infection 
by murine cytomegalovirus (112).  Free transit between polarized cells by adenovirus is 
facilitated by interactions of its attachment protein, fiber, with its junction-associated 
receptor, CAR, disrupting junctional integrity (144).  Penetration of endothelial cells via 
transcytosis efficiently transports adeno-associated virus (34) and HIV-1 (53) across 
endothelial cells.  A final means of viral entry into the bloodstream is via infection of 
peripheral blood leukocytes.  Colorado tick fever virus, a member of the Reoviridae 
family, replicates in erythroblasts in the bone marrow and disseminates systemically 
within erythrocytes (95).  Despite knowledge of the possible mechanisms by which 
viruses gain access to the bloodstream, until this work, it was unclear how reovirus 
establishes viremia. 
 
The role of JAM-A in reovirus dissemination 
Data presented in Chapter II provide evidence that reovirus interactions with 
JAM-A are required for replication in target organs and production of encephalitis but 
surprisingly dispensable for intestinal replication following peroral inoculation.  Failure 
of reovirus to cause encephalitis in JAM-A-/- mice following peroral inoculation is not due 
to an intrinsic block to reovirus replication in JAM-A-/- neural tissues.  Intracranial 
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inoculation studies presented in Chapter III demonstrate that interactions of reovirus with 
JAM-A are not essential for reovirus encephalitis and replication in the murine CNS.  
Instead, expression of JAM-A is required for reovirus dissemination in the host. 
Reovirus strains disseminate systemically via hematogenous, neural, or both 
routes (44, 61, 85, 136).  Data presented in Chapter IV provide evidence that reovirus 
interactions with JAM-A are required for efficient hematogenous dissemination.  In 
particular, lymphatic spread of T1L from intestine to MLN is diminished in JAM-A-/- 
animals compared to wild-type animals.  Furthermore, JAM-A is required for reovirus 
infection of primary endothelial cells.  Thus, both spread through lymphatics and infection 
of endothelial cells are impaired in JAM-A-/- animals. 
How might JAM-A promote entry of reovirus into the lymph and bloodstream?  I 
envision four possibilities.  First, virus binding to JAM-A might lead to productive 
infection of lymphatic and blood endothelial cells with subsequent apical release of 
progeny virions into the circulation.  In support of this idea, reovirus infection of 
polarized airway epithelial cells leads to apical release of virus with little detectable 
cytopathic effect (43).  Second, JAM-A might be required for reovirus particles to traffic 
between endothelial cells, analogous to interactions of adenovirus with polarized cells.  
Although reovirus does not appear to disrupt epithelial tight junctions (43), it is possible 
that reovirus disrupts JAM-A interactions in endothelial tight junctions to permit 
bloodstream entry.  Third, JAM-A might be required for reovirus transport through 
endothelial cells via a transcellular pathway.  Caveolae-mediated transcytosis efficiently 
transports extracellular molecules across endothelial cells in a receptor-specific and cell 
type-specific manner (100).  It is possible that reovirus transcytoses through endothelial 
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cells via a similar mechanism dependent on JAM-A.  Fourth, JAM-A might be required 
for infection of peripheral blood leukocytes that transport reovirus in lymphatic and 
bloodstream circulation.  Although reovirus infects both wild-type and JAM-A-/- 
mononuclear cells of PPs, which comprise the gut-associated lymphatic tissue, the role of 
JAM-A in reovirus infection of leukocytes has not been determined. 
Reovirus has been observed to be free in the plasma and associated with cells 
(60).  Immunofluorescence and EM studies have demonstrated that viremic reovirus is 
observed in extracellular and macrophagic membrane-bound structures, cell-free 
aggregates, and leukocytes (60).  Therefore, it is possible that reovirus establishes 
viremia through more than one mechanism.  Results in this thesis indicate that JAM-A 
mediates a primary route of viremic access.  It is conceivable that JAM-A-independent 
mechanisms account for a minority of viral bloodstream dissemination, accounting for 
the low levels of viremia in JAM-A-/- mice.  
 
Future directions 
It is not known how JAM-A promotes lymphatic and circulatory access to 
reovirus in the infected host.  Data presented in Chapter IV demonstrate that JAM-A is 
required for reovirus infection of nonpolarized primary endothelial cells, but this 
experiment probably does not mimic the conditions in which reovirus infects endothelial 
cells in vivo.  To test whether JAM-A is required for reovirus infection of polarized 
endothelial cells, primary endothelial cells should be isolated from wild-type and JAM-A-
/- mice and plated in densities to promote polarization.  T1 and T3 reovirus infection of 
these cells from the apical and basolateral surfaces should be compared.  In addition, it 
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should be determined whether progeny virions are released from the apical or basolateral 
surface.  These experiments will elucidate the role of JAM-A in reovirus infection of 
polarized endothelial cells.  Immunohistochemical analysis of endothelial infection of 
intestine and target organs following peroral inoculation with reovirus will clarify 
whether endothelial cell infection occurs at sites from which virus accesses the 
bloodstream and at sites to which virus egresses from the bloodstream into target organ 
tissue.  Furthermore, mice have been generated that do not express JAM-A in endothelial 
cells (19).  Studies of reovirus pathogenesis similar to those presented in Chapters II and 
III using these mice will definitively determine whether JAM-A expression by 
endothelial cells is the primary determinant of hematogenous dissemination of reovirus. 
It is possible that JAM-A is required for reovirus infection of blood leukocytes.  
Reovirus may be transported in the bloodstream by these cells, analogous to the related 
Colorado tick fever virus.  Reoviruses replicate in splenic mononuclear cells of neonatal 
mice (128), and reovirus infects peripheral lymphatic tissues such as the spleen and PPs 
(45, 61, 85, 155).  To test whether JAM-A is required for reovirus infection of 
leukocytes, splenocytes from neonatal wild-type and JAM-A-/- mice should be isolated 
and infected with T1 and T3 reovirus strains.  If JAM-A-/- splenocytes demonstrate 
reduced capacity to support reovirus infection, splenocytes from these and wild-type 
animals should be flow sorted by cell type before infection with T1 and T3 reovirus 
strains.  These experiments will clarify which leukocytic populations reovirus targets and 
which populations require JAM-A for infection.  Collectively, these studies will 
contribute to a greater understanding of how reovirus establishes viremia and elucidate 
the cells types that require JAM-A for hematogenous dissemination of reovirus. 
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The role of IgSF receptors in viral pathogenesis 
Diverse families of viruses bind immunoglobulin superfamily (IgSF) proteins 
located in TJs and adherens junctions of epithelium and endothelium.  However, little is 
known about the roles of these receptors in the pathogenesis of viral disease.  In addition 
to the work presented here, there are only two other studies that have explored functions 
of IgSF virus receptors in viral pathogenesis: nectin-1 and herpes simplex virus-2 (HSV-
2) infection of mice and carcinoembryonic antigen-related cell adhesion molecule 1a 
(CEACAM1a) and mouse hepatitis virus (MHV) infection of mice.   
HSV uses three cell-surface molecules to mediate entry into cells: herpesvirus 
entry mediator (HVEM), nectin-1, and nectin-2 (27, 49, 84, 145).  Nectins, like JAMs, 
are IgSF molecules involved in cell adhesion (127).  Nectin-1, also called poliovirus 
receptor-related 1 (PVRL1), is widely expressed and found in neural, epithelial, stromal, 
endothelial, and lymphoid cells (54).  As with reovirus and JAM-A, absence of nectin-1 
attenuates HSV-2 virulence in intravaginally inoculated Pvrl1-/- mice.  Unlike JAM-A 
and reovirus, Pvrl1-/- mice exhibit reduced efficiency of infection by HSV-2 at the site of 
primary replication, the vaginal epithelium.  Replication at this site requires either nectin-
1 or HVEM, which is a member of the tumor necrosis factor receptor family.  In addition, 
spread of HSV-2 to the dorsal root ganglia and spinal cord is impaired in these animals.  
Although a subset of Pvrl1-/- mice succumb to HSV infection, these animals are protected 
from development of external signs of disease, including hair loss, inflammation, and 
skin lesions, indicating that nectin-1 mediates spread from vaginal epithelium to perineal 
skin and surrounding areas (129).  In contrast to mice lacking nectin-1, mice lacking 
HVEM do not exhibit alterations in HSV-2 vaginal infection, external lesions, or viral 
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loads in the peripheral nervous system or CNS.  Thus, IgSF member nectin-1 mediates 
HSV-2 infection in the vaginal epithelium, spread to perineal skin, and dissemination to 
the CNS.  
CEACAM1a serves as a receptor for the coronavirus MHV and also binds several 
bacteria, including Escherichia coli, Neisseria gonorrhoeae, N. meningitidis, and 
Haemophilus influenzae.  CEACAM1a is a glycosylated protein expressed as four 
isoforms with either two or four Ig domains.  CEACAM1a is widely expressed on 
epithelial cells, is found on various leukocytes, is expressed at low levels on glial cells in 
the nervous system, and is inducible on endothelial cells and T cells (69).  Ceacam1a-/- 
mice are completely resistant to intranasal and intracerebral inoculation of MHV strain 
A59 (58).  However, Ceacam1a-/- mice will succumb to a more neurovirulent strain of 
MHV, strain JHM, at inoculation doses 100-fold higher than those required for morbidity 
in wild-type mice (83).  The capacity of MHV-JHM to kill Ceacam1a-/- mice is either due 
to alternative receptor utilization by this viral strain or a receptor-independent means of 
spread.  Receptor-independent spread of MHV occurs when the viral spike glycoprotein, 
which mediates viral attachment and fusion, is expressed at the surface of infected cells 
and induces fusion of infected cells with uninfected cells to promote direct cell-to-cell 
spread of virus (83).  Thus, although CEACAM1a promotes efficient replication of MHV 
strains in vivo, the requirement for CEACAM1a expression for MHV disease is strain-
specific. 
 CEACAM1a is required for infection by MHV A59 at all sites.  In contrast, 
expression of JAM-A and nectin-1 are not absolute requirements for viral replication of 
reovirus in the intestine and HSV-2 in the vaginal epithelium, respectively.  In the case of 
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HSV-2, HVEM contributes to vaginal epithelial infection.  In the case of reovirus, a virus 
receptor other than JAM-A likely mediates infection in the intestine.  Strikingly, the IgSF 
molecules JAM-A and nectin-1 both mediate spread of virus from the site of primary 
replication to target organs.  These observations raise the possibility of a conserved 
mechanism of dissemination specific to the interactions of viruses with their IgSF 
receptors. 
 
Evidence for currently-unknown reovirus receptors 
The exquisite neural tropism of reovirus in newborn mice is restricted to T3 
strains (65, 78, 102).  T3SA- does not bind sialic acid (3), a carbohydrate coreceptor used 
by some T3 reovirus strains (32).  That JAM-A is not required for reovirus T3SA- 
replication in the intestine or brain suggests the existence of novel receptors for reovirus at 
those sites.  In parallel with these findings, analysis of histologic brain sections indicates 
that T3SA- infects the same regions of wild-type and JAM-A-/- mouse brains: the cortex, 
CA2-4 regions of the hippocampus, thalamus, and cerebellar Purkinje cells.  This 
regional tropism is identical to that observed using sialic acid-binding T3 reovirus strains 
(31, 105).  Moreover, genetic deletion of JAM-A does not alter reovirus infection of 
primary cultures of neurons.  Based on findings reported here, I hypothesize that reovirus 
replication in neurons is mediated by a serotype-specific receptor other than JAM-A or 
sialic acid.  In addition, since both T1 and T3 reovirus strains can replicate in the 
intestines of JAM-A-/- mice, I propose that reovirus infection at that site is mediated by a 
serotype-independent receptor or a receptor-independent uptake mechanism. 
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 To identify receptors that mediate reovirus infection of neurons, proteomic, 
genomic, and bioinformatic approaches should be used.  A virus-on-protein-binding 
assay (VOPBA) utilizing radiolabeled reovirus particles and membrane protein 
preparations from JAM-A-/- primary murine cortical cultures, combined with protein 
identification by mass spectrometry, should be used as a first step to identify candidate 
receptors.  A screening approach using existing neural cDNA libraries or a cDNA library 
generated from JAM-A-/- primary cortical neurons can also be used identify a neural-
specific reovirus receptor.  Utilizing knowledge of reovirus tropism in the brain generated 
in this thesis and reported in the literature (133), a database of gene-expression patterns in 
the mouse brain such as the gene expression nervous system atlas (GENSAT) database 
(159) can be searched for receptor-like proteins expressed in reovirus-targeted regions 
while excluding those expressed in regions refractory to reovirus infection, generating a 
pool of potential reovirus receptors. 
 
Conclusion 
The finding that an individual viral receptor can mediate a specific step in 
pathogenesis has important implications for antiviral strategies.  For example, while 
genetic deletion of JAM-A protects mice from reovirus morbidity and mortality 
following peroral inoculation, these animals are capable of viral transmission to new 
hosts.  Uninoculated littermates of infected JAM-A-/- mice develop high titers of reovirus 
in the intestine, suggesting that viral shedding occurs in infected JAM-A-/- mice 
(Appendix A).  In this viral model, pharmacological blockade of reovirus-JAM-A 
interactions would diminish disease in treated individuals but have no effect on viral 
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transmission between hosts, an observation that merits consideration in other viral 
diseases.   
Establishment of viremia is a poorly understood process for most viruses.  My 
work shows that the establishment of reovirus viremia depends on virus interactions with 
JAM-A.  Further dissection of how JAM-A mediates viremic access may provide clues 
about mechanisms of systemic dissemination of adenovirus, coxsackievirus, herpes 
simplex virus, and poliovirus, which also employ junction-associated IgSF members as 
receptors.  Moreover, our finding that a broadly-expressed receptor mediates an 
exquisitely specific aspect of viral pathogenesis suggests that virus-host interactions 
require multiple receptors that serve unique functions at each step of the disease process. 
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Cell lines, viruses, and antibodies 
L cells were maintained as described (3).  Reovirus strains T1L and T3D are 
laboratory stocks.  T3/C44-SA- (T3SA-) was generated as described (3).  Virus was 
purified after growth in L cells by CsCl-gradient centrifugation (48).  Viral titers were 
determined either by plaque assay (141) or fluorescent focus assay (3).  Immunoglobulin 
G (IgG) fractions of rabbit antisera raised against T1L and T3D (151) were purified by 
protein A-Sepharose (3).  Fluorescently conjugated secondary Alexa antibodies were 
obtained from Molecular Probes (Invitrogen).  Murine mAbs 9BG5 (17) and 5C6 (142) 
were purified from hybridoma supernatants (Cell Culture Center, Minneapolis, MN). 
 
Mice 
C57BL/6J (wild-type, JAM-A+/+) were obtained from Jackson Laboratory.  JAM-
A-/- mice (19) were provided by T. Sato (Cornell University, New York, NY) and 
backcrossed for ten generations on a C57BL/6J background strain.  Disruption of the 
JAM-A gene was confirmed by PCR.   
 
Primary cells 
MEFs were maintained in Dulbecco's modified Eagle's medium (Gibco) 
supplemented to contain 10% FBS (Gibco), 1x MEM non-essential amino acids, 2 mM 
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L-glutamine, 0.1 mM 2-mercaptoethanol, 20mM HEPES, 100 units/ml penicillin, 100 
µg/ml streptomycin, and 0.25 µg/ml amphotericin B.  Experiments were performed using 
MEFs following the third to fifth passage. 
Primary mouse cortical cultures were derived from cortices of E15 wild-type and 
JAM-A-/- embryos.  Fetuses were decapitated, brains were removed, and cortical lobes 
were dissected and submerged in Hanks’ balanced salt solution (Gibco) on ice.  Cortices 
were incubated in 0.6 mg/ml trypsin solution at RT for 30 min, washed twice, and then 
manually dissociated twice with a pasteur pipette.  Settled aggregates were discarded.  
Viable cells, quantified by trypan blue staining, were plated at a density of 2.75 x 105 
cells/ml in 24-well plates (Costar) or on glass coverslips placed in 24-well plates (BD).  
Wells were treated prior to plating with a 10 µg/ml poly-D-lysine solution (BD) and a 
1.64 µg/ml laminin solution (BD).  Cultures were incubated for the first 24 h in 
neurobasal media (Gibco) supplemented to contain 10% FBS (Gibco), 0.6 mM L-
glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin.  Cultures were thereafter 
maintained in neurobasal media supplemented to contain 10 ml 50X B27 (Gibco), 50 
units/ml penicillin, and 50 µg/ml streptomycin.  A 50% medium change was performed 
every 3-4 days.  Neurons were allowed to mature for 7 days prior to use.  
Primary mouse lung endothelial cells were derived from two- to four-month old 
wild-type and JAM-A-/- mice.  Mice were euthanized and the lung vasculature was 
perfused via the right ventricle with PBS supplemented to contain 2 mM EDTA followed 
by 0.25% trypsin (Invitrogen) supplemented to contain 2 mM EDTA.  Heart and lungs 
were removed en bloc and incubated at 37°C for 20 min.  The visceral pleura was 
trimmed away, and the perfusion was repeated.  Primary endothelial cells were recovered 
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and grown on tissue culture plastic for 12 days in EGM-2 Basal Medium (Clonetics) 
supplemented to contain EGM-2 MV SingleQuot (Clonetics) prior to use.   
 
Viral infectivity 
Monolayers of cells were adsorbed with reovirus at various MOIs, fixed after 20 
h, stained, visualized by indirect immunofluorescence, and quantified as described (3).  
When indicated, A. ureafaciens neuraminidase (Sigma) was applied to cells at 37°C for 
60 min prior to infection with reovirus.  When indicated, 9BG5 and 5C6 were added to 
virus preparations before infection of cells. 
 
Virus replication 
Monolayers of cells in 24-well plates (Costar) were adsorbed with reovirus at an 
MOI of 2 PFU/cell, washed with PBS, and incubated for various intervals.  Cells were 
frozen and thawed twice prior to viral titer determination by plaque assay using L cells.  
Viral yields were calculated according to the following formula: log10 yieldtx = log10 
(PFU/ml)tx – log10 (PFU/ml)t0, where tx is the time post infection. 
 
Infection of mice 
Two- and three-day old mice weighing 1.5-2 grams were inoculated perorally 
(108), intracranially (135), or intramuscularly with purified reovirus diluted in PBS.  For 
analysis of virulence, mice were monitored for weight loss and symptoms of disease for 
21 days post-inoculation and euthanized when found to be moribund.  For analysis of 
viral replication, mice were euthanized at various intervals following inoculation, and 
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organs were harvested into 1 ml of PBS, frozen and thawed three times, and 
homogenized by sonication.  For analysis of viremia, mice were decapitated at various 
intervals following inoculation, and whole blood was collected from the neck into a 1 ml 
syringe containing 100 µl Alsever’s solution (Sigma).  Blood in Alsever’s solution was 
frozen and thawed three times and homogenized by sonication.  Viral titers in organ 
homogenates and blood were determined by plaque assay.  Animal husbandry and 
experimental procedures were performed in accordance with Public Health Service policy 
and approved by the Vanderbilt University School of Medicine Institutional Animal Care 
and Use Committee. 
 
Histology 
Two- and three-day old mice weighing 1.5-2 grams were inoculated intracranially 
or perorally with purified reovirus diluted in PBS.  At various intervals following 
inoculation, mice were euthanized and organs were collected.  Brains were bisected 
sagittally and the right hemispheres were processed for histopathologic analysis.  Peyer’s 
patches and surrounding tissue were collected from the small intestine and processed for 
histopathologic analysis.  Tissues were incubated in 10% formalin at RT for 24 h 
followed by incubation in 70% ethanol at RT.  Fixed organs were embedded in paraffin, 
and 6-µm coronal sections were prepared.  Consecutively obtained sections were stained 
with H&E for evaluation of histopathologic changes or processed for 
immunohistochemical detection of reovirus protein. 
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JAM-A IS NOT REQUIRED FOR TRANSMISSION OF REOVIRUS  
BETWEEN LITTERMATES 
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Introduction 
 
Reovirus strains are capable of transmission from perorally infected newborn 
mice to naïve littermates.  T1L and T3 clone 9 are successfully transmitted to 
uninoculated littermates a majority of the time, whereas T3D is rarely transmitted to 
littermates (63).  This capacity for reovirus transmission between hosts segregates with 
the L2 gene segment (63).  L2 encodes λ2, a viral protein that forms pentamers from 
which σ1 extends and through which viral messenger RNA extrudes during transcription 
(114). 
This thesis presents results indicating that JAM-A is required for dissemination of 
reovirus within the host.  However, it is not known whether expression of JAM-A is 
required for transmission of reovirus between hosts.  In this study, I used wild-type and 
JAM-A-/- mice to determine the extent to which JAM-A is required for transmission of 
reovirus among littermates.  I found that JAM-A is not required for animal-to-animal 
transmission of reovirus.   
 
Results 
To determine the function of JAM-A in reovirus transmission between littermates, 
I selected two newborn wild-type and JAM-A-/- mice from litters of eight for peroral 
inoculation with 104 PFU of T3SA-.  I isolated the role of JAM-A from the role of sialic 
acid in reovirus transmission by using T3SA-, a reovirus strain incapable of binding sialic 
acid (3).  The remaining six mice in each litter received no treatment.  Litters were 
reunited immediately following inoculation.  I observed and marked infected mice daily 
and quantified viral titers in various organs of all mice twelve days post-inoculation.  
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T3SA- replication was observed in the intestines of all inoculated wild-type and JAM-A-/- 
mice (Figure 1).  All uninoculated JAM-A-/- littermates displayed robust intestinal 
replication, whereas only two of six uninoculated wild-type littermates harbored viral 
titer in the intestines (Figure 1).  These results indicate that JAM-A is not required for 
transmission of reovirus between littermates.  Analogous to results presented in Chapter 
II, replication in the brain of inoculated wild-type mice is much greater than that seen in 
inoculated JAM-A-/- mice (Figure 1).  However, no viral replication in the brain was 
observed in any of the uninoculated JAM-A-/- mice and in all except one of the 
uninoculated wild-type mice (Figure 1).  These results confirm that, even though reovirus 
is transmitted between JAM-A-/- mice, all JAM-A-/- mice are protected from disease. 
 
 
 
FIGURE 1. Transmission of reovirus between littermates is not dependent on JAM-A. Two 
newborn JAM-A+/+ and two newborn JAM-A-/- mice from litters of eight were inoculated 
perorally with 104 PFU T3SA- and placed back with uninfected littermates. At day 12 after 
inoculation, mice were euthanized, intestines and brains were resected, and viral titers were 
determined by plaque assay. Each data point represents one animal. Horizontal bars indicate 
the arithmetic mean of log-transformed data. 
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Discussion 
 I have demonstrated in Chapter II that T3SA- viral replication in the intestine of 
wild-type and JAM-A-/- mice is equivalent.  In Chapter IV, I present histologic evidence 
indicating that no substantial differences in reovirus intestinal tropism exist between 
wild-type and JAM-A-/- mice.  Moreover, transmission of reovirus between hosts has been 
shown to segregate with the viral L2 gene (63).  Therefore, it is not surprising that work 
presented in this section demonstrates that JAM-A expression is not required for reovirus 
transmission between hosts. 
 As discussed in Chapter V, work presented in this thesis suggests the existence of 
an unidentified reovirus intestinal receptor.  I hypothesize that reovirus engagement of 
this receptor is required for viral replication in the intestine and also for transmission 
between hosts.  It has not been definitively shown that the reovirus L2 gene is important 
for viral replication in the intestine, but it is possible that this gene mediates engagement 
of an intestinal receptor, release from the intestinal cells into the intestinal lumen, or 
stability of reovirus in the environment (12, 63).  Nonetheless, this experiment 
demonstrates that the role of JAM-A in reovirus pathogenesis is limited to viral 
dissemination within - but not between - hosts. 
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Mammalian orthoreoviruses (reoviruses) are
highly tractable experimental models for stud-
ies of double-stranded (ds) RNA virus rep-
lication and pathogenesis. Reoviruses infect
respiratory and intestinal epithelium and dis-
seminate systemically in newborn animals. Until
now, a strategy to rescue infectious virus from
cloned cDNA has not been available for any
member of the Reoviridae family of dsRNA
viruses. We report the generation of viable reo-
virus following plasmid transfection of murine
L929 (L) cells using a strategy free of helper vi-
rus and independent of selection. We used the
reovirus reverse genetics system to introduce
mutations into viral capsid proteins s1 and s3
and to rescue a virus that expresses a green
fluorescent protein (GFP) transgene, thus dem-
onstrating the tractability of this technology.
The plasmid-based reverse genetics approach
described here can be exploited for studies
of reovirus replication and pathogenesis and
used to develop reovirus as a vaccine vector.
INTRODUCTION
Reoviruses are members of the Reoviridae family, which
includes several genera that cause disease in humans
and animals. Chief among these are the rotaviruses, which
are the most common cause of viral gastroenteritis in hu-
man infants (Kapikian et al., 2001). Reoviruses infect the
respiratory and gastrointestinal tracts of virtually all mam-
mals, including humans (Tyler, 2001). However, disease
associated with reovirus infection occurs primarily in the
very young (Tyler et al., 2004). Reoviruses are highly viru-
lent in newborn mice, the preferred experimental system
for studies of reovirus pathogenesis, and produce injuryCeto a variety of host tissues, including the central nervous
system (CNS), heart, and liver (Tyler, 2001).
Reoviruses contain a genome of 10 dsRNA gene seg-
ments enclosed in two concentric protein shells, termed
outer capsid and core. Reovirus infection is initiated by
viral attachment to host cells via the filamentous attach-
ment protein s1 (Furlong et al., 1988). The s1 protein en-
gages cell-surface carbohydrate (Chappell et al., 1997,
2000) and junctional adhesion molecule-A (JAM-A) (Bar-
ton et al., 2001b; Campbell et al., 2005), an integral com-
ponent of intercellular tight junctions (Martin-Padura et al.,
1998). Following attachment to the cell surface, reovirus
internalization is mediated by b1 integrins (Maginnis
et al., 2006), most likely via clathrin-dependent endocyto-
sis (Ehrlich et al., 2004). In the endocytic compartment, vi-
ral outer-capsid proteins s3 and m1/m1C are cleaved by
acid-dependent cysteine proteases (Baer and Dermody,
1997; Ebert et al., 2002), resulting in generation of infec-
tious subvirion particles (ISVPs) (Borsa et al., 1981). During
ISVP formation, s3 is removed and a hydrophobic con-
former of m1/m1C is exposed, facilitating endosomal mem-
brane penetration and delivery of transcriptionally active
reovirus core particles into the cytoplasm (Chandran
et al., 2002; Odegard et al., 2004), where the remainder
of the replication cycle occurs.
With the exception of dsRNA viruses, a plasmid-based
reverse genetics system exists for all major groups of an-
imal RNA viruses, including bornaviruses, bunyaviruses,
coronaviruses, flaviviruses, orthomyxoviruses, paramyxo-
viruses, picornaviruses, and rhabdoviruses (Table S1 in
the Supplemental Data available with this article online).
Despite extensive efforts in several laboratories, genera-
tion of an animal dsRNA virus entirely from cloned cDNAs
has not been achieved. This critical technological gap is
perhaps the single most important limitation to studies
of these viruses. Previous efforts on reovirus and rotavirus
reverse genetics have resulted in entirely RNA-based
(Roner et al., 1997) or partially plasmid-based (Komoto
et al., 2006) systems that permit replacement of one or
two viral genes. These approaches have been used toll Host & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 147
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Reverse Genetics for ReovirusFigure 1. Experimental Strategy to Generate Reovirus from Cloned cDNA
(A) Prototype reovirus gene segment cDNA in plasmid. Cloned cDNAs representing each of the ten full-length reovirus RNA gene segments are
flanked by the bacteriophage T7 RNA polymerase promoter (T7P) and the antigenomic hepatitis delta virus (HDV) ribozyme (Rib).
(B) Schematic of approach. The ten reovirus cDNA constructs are transfected into murine L cells expressing T7 RNA polymerase from recombinant
vaccinia virus strain rDIs-T7pol, which is replication defective. Nascent transcripts correspond to viral mRNAs containing the native 50 end. Self
cleavage by the HDV ribozyme generates the native viral 30 end. Following 5 days of incubation, transfected cells are lysed by freeze-thaw, and viable
viruses rescued from cloned cDNAs are isolated by plaque assay using L cells.
(C) Kinetics of virus production following plasmid transfection of L cells. Cells were transfected with plasmid DNA according to the protocol in (B) and
lysed at the intervals shown. Viral titers in cell lysates were determined by plaque assay.
(D) Infectious center assay following plasmid transfection of L cells. Cells were transfected with plasmid DNA, trypsinized at the intervals shown post-
transfection, washed, counted, diluted, and applied directly to monolayers of untreated L cells. The number of the infectious centers was determined
by plaque assay.rescue temperature-sensitive reovirus strains (Roner
et al., 1997), define packaging signals in reovirus RNAs
(Roner and Steele, 2007), and isolate rotaviruses contain-
ing engineered changes in the viral attachment protein
(Komoto et al., 2006). However, neither the reovirus nor
rotavirus reverse genetics systems in their current config-
urations permit selective introduction and recovery of
desired mutations in each viral gene segment.
We report the development of an entirely plasmid-
based reverse genetics system for mammalian reovirus
in which viable viruses are generated from cloned cDNAs.
Neither helper virus nor coexpression of viral replication
proteins is required for recovery of wild-type (WT) virus
or engineered viral mutants. Point mutations introduced
into viral capsid proteins s1 and s3 were used to define
sequences that govern susceptibility to cleavage by intes-
tinal proteases. We also recovered a recombinant virus
that expresses green fluorescent protein (GFP) by re-
placement of the s3 open reading frame (ORF) with
GFP. The establishment of plasmid-based reverse genet-
ics for reovirus will allow heretofore technically unap-
proachable problems in dsRNA virus biology to be stud-
ied, provide a platform for development of analogous
marker rescue systems for other segmented dsRNA
viruses, and foster exploration of reovirus as a vaccine148 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elseviervector to elicit protective immunity against a variety of
mucosal pathogens.
RESULTS
Generation of Viable Reovirus from Cloned cDNA
To generate recombinant reovirus from cloned cDNAs,
plasmids encoding each of the ten viral gene segments
were engineered to facilitate transcription of full-length vi-
ral mRNAs under control of the bacteriophage T7 RNA
polymerase promoter, which directs transcription initia-
tion preferentially from a juxtaposed guanosine residue
(Milligan et al., 1987). As all reovirus (+)-sense RNAs are
terminated with a 50 guanosine (Furuichi et al., 1975a,
1975b), plasmid-generated transcripts are anticipated to
possess native 50 ends (Roner and Joklik, 2001) (Fig-
ure 1A). Murine L929 fibroblast (L) cells, which efficiently
support reovirus replication (Barton et al., 2001a), were in-
fected with the attenuated, T7 RNA polymerase-express-
ing vaccinia virus strain rDIs-T7pol 1 hr prior to transfec-
tion with the ten reovirus cDNA plasmids (Figure 1B).
Nascent transcripts were synthesized with the hepatitis
delta virus (HDV) ribozyme fused to the 30 terminus, which
is expected to generate a native 30 end upon autocatalytic
removal (Roner and Joklik, 2001) (Figure 1A). Thus, thisInc.
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T1LS1
(A) Electropherotypes of T1L, T3D, rsT3D, and
rsT3D/T1LS1. Viral dsRNA was extracted from
purified virions and electrophoresed in an
SDS-polyacrylamide gel, followed by ethidium
bromide staining to visualize viral gene seg-
ments. Size classes of gene segments (L, M,
S) are indicated.
(B) Recombinant viruses contain a novel muta-
tion in the L1 gene. The single nucleotide differ-
ence in L1 unique to rsT3D and rsT3D/T1LS1
is shown in the alignment as an asterisk. The
G/A substitution at position 2205 is a signa-
ture change engineered into the cloned T3D
L1 cDNA used for marker rescue.
(C) Sequence analysis of L1 gene RT-PCR
products from rescued reoviruses. A fragment
of the L1 gene was amplified by one-step RT-PCR performed using viral dsRNA extracted from purified virions of T3D, rsT3D, and rsT3D/T1LS1.
Products were subjected to direct sequence analysis and compared to the L1 sequence of T3D. Shown are sequence chromatograms demonstrating
G/A substitution at position 2205 of the rsT3D and rsT3D/T1LS1 L1 genes.expression strategy should yield ten unique reovirus
mRNA species competent to complete all steps in the viral
RNA life cycle. Accordingly, rescued viruses were recov-
ered from cell-culture supernatants by plaque assay on
L cell monolayers (Figure 1C).
To ensure that viruses isolated following plasmid trans-
fection represented single clones, and to preclude con-
tamination of reovirus stocks by rDIs-T7pol, all viruses
were isolated by plaque purification using L cell mono-
layers. rDIs-T7pol is replication defective and produces
no detectable growth in mammalian cells (Ishii et al.,
2002). Concordantly, no viral plaques arose on L cell
monolayers when the cotransfections were prepared
with nine of the ten reovirus marker-rescue plasmids
(data not shown). Furthermore, vaccinia virus proteins
were not detected by immunoblot analysis of second-
passage stocks of plaque-purified reoviruses (data not
shown).
Infectious center assays were performed to assess the
efficiency of reovirus infection in plasmid-transfected L
cells. At 24–48 hr posttransfection, times corresponding
to the primary round of infection, eight or fewer infectious
centers per 106 cells were detected (Figure 1D). The num-
ber of infectious centers increased substantially between
48 and 72 hr posttransfection to 18 to 90 per 106 cells,
suggesting that a secondary round of infection had en-
sued by the 72 hr time point. Viral titer in transfection ly-
sates was below the limit of detection (10 PFU/ml) at
24 hr but was detectable at 48 hr and increased logarith-
mically at time points thereafter (Figure 1C). The ratio of
viral PFU in transfection lysates to infectious centers
was 10 to 100 at 48 and 72 hr. These results indicate
that initiation of productive reovirus replication from trans-
fected plasmids is inefficient, with approximately 1 cell per
105 to 106 cells giving rise to, on average, 10 to 100 viable
virus particles that establish infection of the culture. In our
experiments, yields of WT virus 5 days after plasmid
transfection are regularly in the range of 104–106 PFU/ml
(Figure 1C).Cell HSeparation of reovirus genomic dsRNA using SDS-
PAGE produces unique electrophoretic patterns that can
be used to discriminate different viral strains (Barton
et al., 2001a). To confirm that viruses isolated using the
plasmid-based rescue procedure contained the expected
combination of gene segments, genomic dsRNA isolated
from recombinant strain (rs) T3D and rsT3D/T1LS1was re-
solved in SDS-polyacrylamide gels and visualized by
ethidium bromide staining (Figure 2A). The electrophero-
type of rsT3D was indistinguishable from that of strain
T3D, the origin of the cloned cDNA sequences used to
generate rsT3D. Likewise, rsT3D/T1LS1 displayed an
electropherotype consistent with nine cloned gene seg-
ments derived from T3D and a single cloned gene seg-
ment, S1, derived from strain T1L. To exclude the possibil-
ity of contamination, a silent point mutation, G to A at
nucleotide 2205, was introduced into the L1 gene of all
virus strains generated from cloned cDNAs (Figure 2B).
This change has not been observed in any reported T3D
L1 sequence (Wiener and Joklik, 1989) and serves as a sig-
nature for viruses derived through plasmid-based rescue.
As anticipated, sequence analysis of rsT3D and rsT3D/
T1LS1 revealed the expected G to A substitution (Fig-
ure 2C), confirming the plasmid origins of these isolates.
Characterization of Reoviruses Generated
by Plasmid Transfection
Reoviruses replicate and assemble within cytoplasmic in-
clusions in infected cells (Fields, 1971). Viral inclusions
contain dsRNA (Silverstein and Schur, 1970), viral proteins
(Fields, 1971), and both complete and incomplete viral
particles (Fields, 1971). Reovirus strain T3D forms large
globular inclusions that localize to the perinuclear space
(Parker et al., 2002). To determine whether rsT3D forms vi-
ral inclusions in a manner similar to native T3D, cells were
infected with T3D and rsT3D and processed 18 hr postin-
fection for image analysis by confocal microscopy (Fig-
ure 3A). Both T3D and rsT3D formed morphologically
indistinguishable large globular inclusions that wereost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 149
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combinant Reoviruses
(A) Immunofluorescence of cells infected with
T3D and rsT3D. L cells were mock infected or
infected with either T3D or rsT3D, stained at
18 hr postinfection with anti-mNS antiserum to
visualize reovirus inclusions (green) and TO-
PRO3 to visualize nuclei (blue), and imaged
by confocal laser scanning microscopy. Rep-
resentative digital fluorescence (top panel)
and DIC images (bottom panel) for mock-,
T3D-, and rsT3D-infected cells are shown.
Scale bar, 10 mM.
(B) One-step growth curve for T1L, T3D, rsT3D,
and rsT3D/T1LS1 in L cells (left) and MEL cells
(right). Cells were infectedwith virus, incubated
for the intervals shown, and lysed by freeze-
thaw. Viral titers in cell lysates were determined
by plaque assay. The results are presented as
the mean viral titers for triplicate experiments.
Error bars indicate SD.localized to the perinuclear compartment. We conclude
that recombinant rsT3D recapitulates a hallmark of native
T3D infection in cultured cells.
To confirm that the recombinant viruses exhibit replica-
tion kinetics similar to the native strains, T1L, T3D, rsT3D,
and rsT3D/T1LS1 were tested for infection of L cells and
MEL cells (Figure 3B). L cells support replication of all reo-
virus strains tested in our laboratory. In contrast, MEL cells
support replication of only sialic acid-binding reovirus
strains (Rubin et al., 1992; Chappell et al., 1997). T1L,
rsT3D/T1LS1, T3D, and rsT3D produced 1000-fold
yields of viral progeny in L cells. However, only sialic
acid-binding strains T3D and rsT3D were capable of effi-
ciently infecting MEL cells, producing yields in each
case of 100-fold, whereas strains T1L and rsT3D/
T1LS1 produced minimal yields of viral progeny in these
cells (<10-fold). Together, these data indicate that re-
combinant reoviruses display replication characteristics
indistinguishable from native strains.
Susceptibility of Attachment Protein s1
to Proteolytic Cleavage Attenuates Reovirus
Intestinal Infection and Systemic Spread
The s1 protein exhibits strain-specific differences in sus-
ceptibility to cleavage following in vitro treatment with in-
testinal proteases to generate ISVPs (Nibert et al., 1995;
Chappell et al., 1998). This difference in cleavage suscep-
tibility segregates with a single amino acid polymorphism150 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elseviein the tail domain of s1 (Figure 4A). Strains with a threonine
at residue 249 in s1 are susceptible to cleavage by trypsin
after Arg245, whereas those with an isoleucine at residue
249 are resistant to cleavage (Chappell et al., 1998). The
importance of sequence polymorphism at residue 249
has been confirmed in studies using expressed protein
(Chappell et al., 1998) and recoated core particles (Chan-
dran et al., 2001) but not with intact virions.
To determine whether the single Thr-Ile polymorphism
at residue 249 in s1 protein is sufficient to alter s1 cleav-
age susceptibility during treatment of virions with intesti-
nal proteases to generate ISVPs, we used plasmid-based
rescue to generate rsT3D-s1T249I, which differs from
rsT3D by the presence of an isoleucine in s1 at residue
249 (Table S2). Purified virions of rsT3D and rsT3D-
s1T249I were treated with trypsin and analyzed by SDS-
PAGE. As expected, a digestion pattern consistent with
formation of ISVPs (loss of s3 protein and generation of
the d fragment of m1C protein) was observed for both vi-
ruses (Figure 4B). However, the stability of rsT3D and
rsT3D-s1T249I s1 proteins differed. The band corre-
sponding to rsT3D s1 diminished in intensity immediately
after trypsin addition until it was eventually undetectable
(Figure 4B). However, the rsT3D-s1T249I s1 band was in-
tact even after 60 min of digestion. Thus, the T249I poly-
morphism is an independent determinant of s1 cleavage
susceptibility.
Proteolytic cleavage of s1 at a site adjacent to Thr249
releases the JAM-A-binding s1 head domain, leading tor Inc.
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(A) Model of s1 generated by adding five b spiral repeats to the N terminus of the crystallized fragment of s1 (Chappell et al., 2002). The three mono-
mers in the crystallized fragment are shown in red, yellow, and blue; themodel is shown in gray. The inset shows an enlarged view of the b spiral region
in s1 that influences susceptibility of the molecule to cleavage by intestinal proteases (Chappell et al., 1998). Side chains of Arg245 and Thr249 are
depicted in ball-and-stick representation.
(B) Electrophoretic analysis of viral structural proteins of rsT3D and rsT3D-s1T249I during treatment with trypsin to generate ISVPs. Purified
35S-methionine-labeled virions were treated with trypsin for the indicated intervals and loaded into wells of a 4%–20% polyacrylamide gradient
gel. After electrophoresis, the gel was prepared for fluorography and exposed to film. Samples of untreated virions appear in the lanes labeled
‘‘V.’’ Viral proteins are labeled. Positions of molecular weight standards (in kDa) are indicated. The experiments shown are representative of two per-
formed for each virus.
(C) Infectivity of rsT3D and rsT3D-s1T249I during treatment with trypsin to generate ISVPs. Purified virions were treated with trypsin at 37C for the
intervals shown. Titers of virus in the treatment mixtures were determined by plaque assay. The results are presented as the mean viral titers for trip-
licate experiments. Error bars indicate SD.diminished viral infectivity (Nibert et al., 1995). To test
whether rsT3D and rsT3D-s1T249I differ in infectivity after
protease treatment to generate ISVPs, purified virions of
each strain were exposed to trypsin for various intervals,
and titers of infectious virus in the treatment mixtures
were determined by plaque assay (Figure 4C). As ob-
served with WT T3D in previous experiments (Nibert
et al., 1995), rsT3D lost infectious titer rapidly after prote-
ase treatment. In contrast, titers of rsT3D-s1T249I re-
mained relatively stable throughout the assay time course.
Loss of infectivity of rsT3D correlated with kinetics of s1
cleavage (compare Figures 4B and 4C), indicating that
changes in viral infectivity after trypsin treatment are gov-
erned by the cleavage state of s1. Furthermore, both phe-
notypes are linked to a single s1 polymorphism at amino
acid 249.
Reovirus strains T1L and T3D differ in the capacity to in-
fect the murine intestine after peroral (PO) inoculation
(Bodkin et al., 1989), a property that segregates with the
viral S1 (encoding s1 and s1s) and L2 (encoding l2) genes
(Bodkin and Fields, 1989). Exposure of T3D to an intestinalCell Hwash results in s1 cleavage (Chappell et al., 1998), raising
the possibility that failure of T3D to infect the intestine is in
part attributable to s1 cleavage susceptibility. To test
whether susceptibility of s1 to proteolytic cleavage is as-
sociated with diminished T3D growth in animals, we as-
sessed the capacity of rsT3D and rsT3D-s1T249I to infect
the intestine and disseminate systemically following PO
inoculation (Figure 5A). Newborn mice were inoculated
perorally with each strain, and viral titers in the intestine
and brain were determined at 4, 8, and 12 days after inoc-
ulation. At all time points tested, titers of rsT3D-s1T249I in
the intestine were greater than those produced by rsT3D.
Furthermore, rsT3D-s1T249I produced greater titers in
the brain at days 8 and 12 than did rsT3D. However,
when inoculated by the intracranial (IC) route, rsT3D and
rsT3D-s1T249I produced equivalent titers (Figure 5B), al-
though rsT3D reached peak titers at earlier time points
than did rsT3D-s1T249I. These findings indicate that
a Thr-Ile polymorphism at amino acid 249 in T3D s1 con-
trols viral growth in the murine intestine and systemic
spread to the CNS.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 151
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Polymorphism in Outer-Capsid Protein s3
Previous studies identified a tyrosine-to-histidine substi-
tution at amino acid 354 in T3D s3 as a key regulator of
the kinetics of virion-to-ISVP conversion in vitro (Wetzel
et al., 1997) and viral resistance to growth inhibition by
the cysteine protease inhibitor E64 (Baer and Dermody,
1997; Ebert et al., 2001). Tyr354 is located in the virion-
distal lobe of s3 adjacent to sites in the protein that are
cleaved during formation of ISVPs (Ebert et al., 2002)
(Figure 6A). The importance of this residue in viral replica-
tion has been deduced by analysis of reassortant viruses
containing WT and mutant s3 proteins (Wetzel et al.,
1997; Ebert et al., 2001; Clark et al., 2006) and analysis
of ISVPs recoated withWT andmutant forms ofs3 (Wilson
et al., 2002; Clark et al., 2006).
To determine whether the Y354H mutation in s3 is suf-
ficient to confer enhanced virion-to-ISVP conversion and
resistance to E64, we generated rsT3D-s3Y354H (Table
S2) and compared this virus to rsT3D for kinetics of s3
proteolysis following protease treatment in vitro. Virions
of each strain were treated with chymotrypsin for various
intervals and processed for analysis of viral structural
proteins by SDS-PAGE (Figure 6B). Treatment of rsT3D
and rsT3D-s3Y354H virions with chymotrypsin resulted
in degradation of s3 and cleavage of m1C to form d, indic-
Figure 5. rsT3D-s1T249I Infects the Murine Intestine and
Disseminates to the CNS
Titers of rsT3D and rsT3D-s1T249I after either PO (A) or IC (B) inocu-
lation. Mice were inoculated with virus and euthanized at the indicated
times postinoculation. Viral titers in organ homogenates were deter-
mined by plaque assay. The limit of detectionwas 100 PFU/ml of organ
homogenate. Each data point represents the average viral titer from 3
to 12 mice. Error bars indicate SD.152 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elsevierative of ISVP formation. Proteolysis of rsT3D-s3Y354H s3
during chymotrypsin treatment occurred with substan-
tially faster kinetics than that of rsT3D s3. This result indi-
cates that amino acid 354 in s3 protein is an independent
determinant of virion susceptibility to proteolytic digestion
and likely functions as an autonomous regulator of viral
disassembly in cellular endosomes.
The role of s3 mutation Y354H in virion disassembly in
cyto was investigated by quantifying yields of rsT3D and
rsT3D-s3Y354H after 24 hr of growth in L cells treated
with 0–200 mM E64 (Figure 6C). Both strains produced
yields of 1000 fold following growth in untreated cells.
However, yields of rsT3D-s3Y354H were 100-fold
greater than those of rsT3D following growth in cells
treated with 200 mM E64 (the highest concentration
tested). Therefore, a single mutation in s3, Y354H, regu-
lates resistance of reovirus to an inhibitor of cysteine pro-
teases within cellular endosomes.
Transduction of GFP by a Recombinant Reovirus
To determine whether reoviruses capable of expressing
a foreign gene can be recovered following plasmid trans-
fection, we introduced sequences encoding GFP into the
s3 ORF of the T3D S4 plasmid (Figure 7A). In this con-
figuration, GFP is expressed as a fusion protein incorpo-
rating amino acids 1–39 of s3 protein at the N terminus.
Recombinant virus rsT3D/S4-GFP was recovered follow-
ing plasmid transfection of L cells stably expressing WT
s3 protein, which is required for propagation of this strain
(Figure S1). RT-PCR analysis using primers specific for
T3DS4andGFPconfirmed incorporation of a recombinant
S4-GFP gene segment into rsT3D/S4-GFP (Figure 7B). In-
fection of L cells with rsT3D/S4-GFP resulted in expres-
sion of GFP and viral inclusion-forming proteins mNS and
sNS but not s3 (Figures 7C and 7D). The capacity of
rsT3D/S4-GFP to express GFP was not altered through
four passages (data not shown). These results demon-
strate that reovirus can be engineered to express foreign
genes.
DISCUSSION
The absence of DNA intermediates in the life cycle of RNA
viruses poses a technical challenge to genetic analysis of
viral phenotypes. Prior to the development of reverse ge-
netics, or ‘‘marker rescue,’’ for RNA viruses of animals, in
which plasmid-borne cDNAs of viral genomes initiate syn-
thesis of replication-competent RNAs, classical Darwinian
methods were used to select viral mutants that could be
subjected to correlative genetic studies—so-called ‘‘for-
ward genetics.’’ However, reverse genetics technology
permits testing of tightly focused, rational hypotheses
about complex questions of virus structure, virus-cell in-
teractions, and viral pathogenesis through direct engi-
neering of the viral genome without a need to devise com-
plicated selection strategies for isolation of viral mutants.
Furthermore, reverse genetics of RNA viruses has sup-
ported rapid generation of vaccines against these and
other infectious agents and propelled their use as geneInc.
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erates Proteolytic Disassembly of Reovirus
(A) Crystal structure of T3D s3 (Olland et al., 2001), in which cathepsin
L cleavage sites are depicted in blue between amino acids 243 and 244
and between 250 and 251 (Ebert et al., 2002). Surrounding residues,
from amino acids 241 to 253, are shown in yellow. The C-terminal res-
idues of s3, from amino acids 340–365, are colored red. Tyr354, which
is altered in several PI (Wetzel et al., 1997), D-EA (Ebert et al., 2001),
and ACA-D viruses (Clark et al., 2006), is shown in green. The virion-
distal end of s3 is at the top of the figure, and the virion-proximal
end and N terminus are at the bottom. The inset shows an enlarged
view of the boxed region of s3 using the same color scheme. Side
chains of amino acids 243, 244, 250, 251, and 354 are depicted in
ball-and-stick representation.
(B) Chymotrypsin treatment of rsT3D and rsT3D-s3Y354H. Purified
virions were treated with chymotrypsin for the indicated intervals
and loaded into wells of 10% polyacrylamide gels. After electrophore-
sis, the gels were stained with Coomassie blue. Viral proteins are la-
beled. The experiments shown are representative of two performed
for each virus.
(C) Growth of rsT3D and rsT3D-s3Y354H in L cells treated with E64. L
cells were preincubated in medium with or without E64 at the concen-
trations shown. The medium was removed, cells were adsorbed withCell Hdelivery vehicles (Blaney et al., 2006; Horimoto and
Kawaoka, 2006; Riezebos-Brilman et al., 2006).
We developed a fully plasmid-based reverse genetics
technology for mammalian reoviruses. This system per-
mits selective introduction of desired mutations into
cloned cDNAs encoding each of the ten viral gene seg-
ments, followed by isolation of mutant viruses from cells
transfected with the plasmid constructs. Moreover, gene
segment cDNAs can be manipulated to facilitate expres-
sion of a transgene. Importantly, recombinant viruses
are generated without a requirement for helper virus and
free of any selection. Thus, this new technology provides
virus for 1 hr, and fresh medium with or without E64 was added. After
24 hr incubation, viral titers in cell lysates were determined by plaque
assay. The results are presented as themean viral yields, calculated by
dividing titer at 24 hr by titer at 0 hr for each concentration of E64, for
triplicate experiments. Error bars indicate SD.
Figure 7. Expression of GFP by rsT3D/S4-GFP
(A) Schematic of pT7-S4GFP. The GFP ORF is flanked by S4 gene nu-
cleotides 1–149 and 769–1196.
(B) RT-PCR analysis of rsT3D and rsT3D/S4-GFP. Viral dsRNAwas ex-
tracted from purified virions and subjected to RT-PCR using primers
specific for T3D S4 and GFP sequences. Numbers delineate the S4
RNA nucleotide position corresponding to the 50 end of S4-specific
primers.
(C) Viral protein expression in cells infected with rsT3D/S4-GFP. L cells
were infected with rsT3D or rsT3D/S4-GFP at an MOI of 1 PFU per cell
and incubated for 24 hr. Cell lysates were analyzed by immunoblotting
using antibodies specific for mNS, sNS, and s3 proteins.
(D) Image analysis of cells infected with rsT3D/S4-GFP. L cells were in-
fected with rsT3D/S4-GFP, stained with antibodies specific for mNS
(blue) and s3 (red) proteins at 24 hr postinfection, and imaged by con-
focal laser scanning microscopy. Scale bar, 10 mM.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 153
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nome in the context of infectious virus.
We used the newly developed plasmid-based reovirus
reverse genetics system to engineer mutations in the s1
and s3 proteins. These proteins form part of the viral outer
capsid, which is responsible for numerous major events in
reovirus interaction with the cell and host, including at-
tachment, disassembly within endosomes, penetration
of cell membranes, induction of apoptosis, growth in the
intestine, pathways of spread, neurovirulence, and tro-
pism within the CNS (for reviews, see Chandran and
Nibert, 2003; O’Donnell et al., 2003; Guglielmi et al., 2006).
Therefore, we initially applied reverse genetics technology
to the study of outer-capsid proteins to better understand
how these proteins mediate critical steps in reovirus
replication and disease.
The infectivity of ISVPs of reovirus strain T1L in L cells is
approximately 10-fold greater than that of T3D ISVPs
(Nibert et al., 1995). This difference in infectivity is hypoth-
esized to be a direct result of s1 cleavage (Nibert et al.,
1995; Chappell et al., 1998), presumably due to removal
of the JAM-A-binding region of the molecule. Although
the T249I substitution in expressed T3D s1 renders it re-
sistant to cleavage by trypsin (Chappell et al., 1998), until
now it has not been possible to define the role of s1 cleav-
age in T3D infectivity for lack of means to generate a mu-
tant T3D virus with the T249I change. This virus has been
generated using reverse genetics, and our findings indi-
cate that cleavage susceptibility of viral attachment pro-
tein s1 due to a single polymorphism at amino acid posi-
tion 249 is the basis for reduced infectivity of T3D ISVPs
relative to virions (Figure 4C) and contributes to dimin-
ished growth of T3D in the murine intestine following PO
inoculation (Figure 5A).
Previous studies of T3D-derived reovirus strains with
altered disassembly kinetics point to a critical role for
sequences in the virion-distal, C-terminal lobe of s3 in
susceptibility to acid-dependent proteolysis. A C-terminal
Y354H mutation in s3 protein of strain T3D was selected
during persistent infection of L cells (PI viruses) (Wetzel
et al., 1997) and by serial passage of virus in L cells treated
with either E64 (D-EA viruses) (Ebert et al., 2001) or ammo-
nium chloride (ACA-D viruses) (Clark et al., 2006). Using
reovirus reverse genetics, the Y354H substitution was in-
troduced into a WT T3D genetic background, and the re-
sultant virus, rsT3D-s3Y354H, demonstrated accelerated
kinetics of s3 cleavage (Figure 6B) and diminished sensi-
tivity to the growth-inhibitory effects of E64 (Figure 6C).
Residue 354 is located in a position thought to be impor-
tant for controlling access to protease-hypersensitive re-
gions in s3, residues 208–214 and 238–242, thereby influ-
encing s3 cleavage kinetics (Jane´-Valbuena et al., 2002).
Therefore, it appears that residue 354 ins3 is a gatekeeper
for the viral outer capsid, serving to regulate the balance
between viral stability and an irreversible, proteolytically
triggered disassembly cascade committing the virion par-
ticle to either replication or inactivation.
We exploited the reovirus reverse genetics system to
develop a gene-delivery vehicle by replacing thes3ORF in154 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elsevierthe S4 plasmid with a GFP-encoding cDNA (Figure 7). The
resultant virus, rsT3D/S4-GFP, expresses GFP through
successive passages in cell culture. These results reveal
the potential for exploitation of reovirus as a gene-trans-
duction vector with application in the development of
new mucosal vaccines, more effective oncolytic agents
(Coffey et al., 1998), and high-level expression of foreign
genes in animal cells. Ideal reovirus vectors will contain
stable s1 proteins and combine excellent extracellular
stability with highly efficient intracellular disassembly.
We find that each of these parameters can be indepen-
dently adjusted through strategic alterations in outer-
capsid proteins. Manipulation of inner-capsid proteins
and the genomic RNA itself should allow construction of
viruses able to circumvent other aspects of virus-cell
and virus-host interactions that pose potential barriers to
antigen and gene delivery by reovirus.
Our results indicate that productive viral infection is es-
tablished in a small fraction of L cells, approximately 1 in
105–106 cells, transfected with plasmids encoding the
ten reovirus gene segments (Figure 1D). Thus, the reovirus
plasmid-based marker rescue system is suited to the iso-
lation of viable viral clones by plaque assay, followed by
expansion in cell culture to attain quantities of virus suffi-
cient for phenotypic analyses. Manipulations that severely
cripple viral replication or particle assembly aremore chal-
lenging to study because these changes may prohibit
virus isolation. However, recovery of a GFP-expressing vi-
rus, rsT3D/S4-GFP, demonstrates that marker rescue of
lethal mutations is possible by transcomplementation (in
this case with WT s3 protein) (Figure 7 and Figure S1).
This result also agrees with our previous finding that inhi-
bition of reovirus replication by RNAi-mediated reduction
of viral protein synthesis is reversible by transcomplemen-
tation with ectopically expressed WT protein (Kobayashi
et al., 2006). Furthermore, transcomplementation allows
precise definition through systematic mutational analysis
of functional domains in reovirus proteins that are essen-
tial for viral replication (Kobayashi et al., 2006). It should
be possible to apply this technique to the newmarker res-
cue system for delineation of structure-function relation-
ships in reovirus proteins and RNA.
Quantitative success of plasmid-initiated reovirus infec-
tion in this reverse genetics system probably is not limited
by the amount of template or transfection efficiency, since
the molar ratio of plasmid to target cell is approximately
5 3 104, and increasing the amount of plasmid does not
effect higher viral yields from cotransfection lysates
(data not shown). Furthermore, it does not appear that in-
fection efficiency is limited by the absence of viral replica-
tion proteins during early steps of replication because
high-level expression of the replication proteins m2, mNS,
and sNS, which collaborate to form viral inclusions in in-
fected cells (Mbisa et al., 2000; Broering et al., 2002;
Becker et al., 2003; Miller et al., 2003), did not enhance
viral recovery (data not shown). Perhaps the presence
of other viral or cellular factors associated with natural
infection by intact virion particles is required for maximal
reovirus infectivity.Inc.
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system has been described for any other dsRNA virus of
animals. Although each genus within this constellation of
viruses bears unique biologic characteristics and physio-
chemical properties, there are nonetheless numerous uni-
fying features of virion particle structure and replication
mechanisms that should allow principles and techniques
established in this study to be applied broadly across the
group. We expect that new insights into mammalian reovi-
rus replication learnedwith the use of this reverse genetics
system will be quickly extrapolated to other Reoviridae
family members, leading to accelerated development of
analogous marker-rescue technologies for those viruses.
EXPERIMENTAL PROCEDURES
Cells and Viruses
L cells and HeLa cells were maintained as described (Barton et al.,
2001a). Reovirus strains T1L and T3D are laboratory stocks originally
obtained from Dr. Bernard Fields. Virus was purified after growth in
L cells by CsCl-gradient centrifugation (Furlong et al., 1988). Purified
35S-methionine-labeled virions were prepared as described (Nibert
et al., 1995). Attenuated vaccinia virus strain rDIs-T7pol expressing
T7 RNA polymerase was propagated in chick embryo fibroblasts as
described (Ishii et al., 2002).
Plasmid Construction
Full-length reovirus cDNAs were amplified by RT-PCR using viral
dsRNA extracted from purified virions as template. Amplified cDNAs
were initially cloned into pBluescript II SK () (Stratagene) for the
T3D L1, L2, and L3 genes or pCR 2.1 (Invitrogen) for the T3D M1,
M2, M3, S1, S2, S3, and S4 genes and the T1L S1 gene (Table S3).
To generate pT7-L1T3D, pT7-L2T3D, pT7-L3T3D, pT7-M1T3D,
pT7-M2T3D, pT7-M3T3D, pT7-S2T3D, pT7-S3T3D, and pT7-S4T3D,
viral cDNA-containing fragments were subcloned into p3E5EGFP (Wa-
tanabe et al., 2004). Viral cDNAs fused at their native 50 termini to the
phage T7 RNA polymerase promoter were inserted into p3E5EGFP
by partial or complete replacement of plasmid sequences encoding
GFP and the Ebola virus leader and trailer, resulting in ligation of native
30 termini to the HDV ribozyme sequence. To generate pBacT7-S1T3D
and pBacT7-S1T1L, encoding the T3D S1 and T1L S1 genes, respec-
tively, S1 cDNAs fused to the T7 promoter and a portion of the HDV ri-
bozyme were first cloned into the BseRI site of p3E5EGFP, and frag-
ments containing the S1 gene flanked 50 by the T7 promoter and 30
by the HDV ribozyme and T7 terminator sequences were subcloned
into the XbaI site of pBacPAK8 (Clontech). pBacT7-S1T3D and pT7-
S4T3D were used as templates to generate mutant constructs
pBacT7-S1T3DT249I and pT7-S4T3DY354H, respectively, by intro-
duction of specific nucleotide substitutions using the QuickChange
site-directed mutagenesis kit (Stratagene) (Table S4). To generate
pT7-S4GFP, S4 nucleotide sequences 150–768 within pT7-S4T3D
were replaced with the GFP ORF. Nucleotide sequences of recombi-
nant plasmids were confirmed by DNA sequencing. Detailed descrip-
tion of cloning strategies is provided in the Supplemental Data.
Plasmid Transfection and Recovery of Recombinant Virus
Monolayers of L cells at approximately 90% confluence (33 106 cells)
in 60 mm dishes (Costar) were infected with rDIs-T7pol at an MOI of
0.5 TCID50. At 1 hr postinfection, cells were cotransfected with ten
plasmid constructs representing the cloned T3D genome—pT7-
L1T3D (2 mg), pT7-L2T3D (2 mg), pT7-L3T3D (2 mg), pT7-M1T3D
(1.75 mg), pT7-M2T3D (1.75 mg), pT7-M3T3D (1.75 mg), pBacT7-
S1T3D (2 mg), pT7-S2T3D (1.5 mg), pT7-S3T3D (1.5 mg), and pT7-
S4T3D (1.5 mg)—using 3 ml of TransIT-LT1 transfection reagent (Mirus)
per microgram of plasmid DNA. Following 0–5 days of incubation,
recombinant virus was isolated from transfected cells by plaque puri-Cell Hfication on monolayers of L cells (Virgin et al., 1988). Electrophoretic
analysis of viral dsRNA was performed as described (Wilson et al.,
1996). Confirmation of mutations in the S1, S4, and L1 genes of
recombinant viruses was performed using the Onestep RT-PCR kit
(Qiagen), gene-specific primer sets, and viral dsRNA extracted from
purified virions as template. PCR products were analyzed following
electrophoresis in Tris-borate-EDTA agarose gels or purified and sub-
jected directly to sequence analysis.
Infectious Center and Viral Yield Assays
L cells were cotransfected with ten plasmids corresponding to the T3D
genome as described. For infectious center assays, transfected cells
were released from plates by trypsin treatment at various intervals
posttransfection, washed, counted, diluted, and applied directly to
monolayers of untreated L cells (Dermody et al., 1995), which were
processed for plaque assay (Virgin et al., 1988). For viral yield assays,
transfected L cells were lysed by freezing and thawing, and viral titers
in cell lysates were determined by plaque assay (Virgin et al., 1988).
Immunofluorescence Detection of Reovirus Infection
Parental L cells or L cell transfectants selected for stable expression of
s3 protein (5 3 104) were plated on glass coverslips in 24-well plates
(Costar) and infected at an MOI of 10,000 (T3D and rsT3D) or 20,000
(rsT3D/S4-GFP) particles per cell. Following incubation at 37C for var-
ious intervals, cells were fixed and stained for mNS and s3 proteins as
described (Maginnis et al., 2006). Images were acquired using a Zeiss
LSM 510 META inverted confocal system (Carl Zeiss) with a Zeiss
inverted Axiovert 200M microscope and a Plan-APOCHROMAT
633/1.4 NA oil immersion DIC objective. Images were processed
using MetaMorph image analysis software (Molecular Devices).
Infectivity of Recombinant Viruses
Monolayers of L or L-s3 cells (2.5 to 5 3 105) in 24-well plates or sus-
pension cultures of MEL cells (53 105 cells/ml) were infectedwith virus
at an MOI of 1–2 PFU/cell. After 1 hr adsorption at room temperature,
the inoculum was removed, cells were washed twice with PBS, and
fresh medium was added. Cells were incubated at 37C for various in-
tervals, and viral titers in cell lysates were determined by plaque assay
(Virgin et al., 1988).
Analysis of Viral Capsid Proteins after Protease Treatment
Purified virions at a concentration of either 23 1012 particles/ml (tryp-
sin) or 9 3 1012 particles/ml (chymotrypsin) were digested with either
50 mg/ml of N a-p-tosyl-L-sulfonyl phenylalanyl chloromethyl ketone-
treated bovine trypsin (Sigma) or 200 mg/ml of Na-p-tosyl-L-lysine
chloromethyl ketone-treated bovine a-chymotrypsin (Sigma) for vari-
ous intervals at either 25C (trypsin) or 8C (chymotrypsin) as described
(Nibert et al., 1995; Wetzel et al., 1997). Protease digestion was
stopped by adding either 0.5 mg/ml soybean trypsin inhibitor (trypsin)
(Sigma) or 5mMphenylmethyl-sulfonyl fluoride (chymotrypsin) (Sigma)
to the treatment mixtures and cooling at 0C. Viral proteins were re-
solved by SDS-PAGE and visualized by either autoradiography (Nibert
et al., 1995) or staining with Coomassie blue (Wetzel et al., 1997).
Infection of Mice
Newborn C57/BL6 mice weighing 2.0–2.5 grams (2–4 days old) were
inoculated perorally or intracranially with 103 or 102 PFU, respectively,
of purified reovirus virions diluted in PBS. PO inoculations (50 ml) were
delivered intragastrically as described (Rubin and Fields, 1980). IC in-
oculations (5 ml) were delivered to the left cerebral hemisphere using
a Hamilton syringe and 30-gauge needle (Tyler et al., 1985). At various
intervals following inoculation, mice were euthanized, and organs were
harvested into 1ml of PBS and homogenized by freezing, thawing, and
sonication. Viral titers in organ homogenates were determined by pla-
que assay (Virgin et al., 1988). Animal husbandry and experimental
procedures were performed in accordance with Public Health Service
policy and approved by the Vanderbilt University School of Medicine
Institutional Animal Care and Use Committee.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 155
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Monolayers of L cells (2 3 105) in 24-well plates were preincubated in
medium supplemented with 0–200 mM E64 (Sigma) for 4 hr. The me-
dium was removed, and cells were adsorbed with virus at an MOI of
2 PFU/cell. After incubation at 4C for 1 hr, the inoculumwas removed,
cells were washed with PBS, and 1 ml of fresh medium supplemented
with 0 to 200 mM E64 was added. Cells were incubated at 37C for
24 hr and frozen and thawed twice. Viral titers in cell lysates were
determined by plaque assay (Virgin et al., 1988).
Generation of s3-Expressing Cells
L cells stably expressing s3 protein (L-s3 cells) were selected by trans-
fection of cells with pCXN-S4T3D, which encodes the entire T3D s3
ORF, and incubation in the presence of 1mg/ml of geneticin (Invitrogen).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, four supplemental tables, and one supplemental figure and
can be foundwith this article online at http://www.cellhostandmicrobe.
com/cgi/content/full/1/2/147/DC1/.
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